Union Calendar No. 596

115TH CONGRESS 2D SESSION

H. R. 5925

[Report No. 115-767, Part I]

To codify provisions relating to the Office of National Drug Control, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

May 23, 2018

Mr. Gowdy (for himself, Mr. Cummings, Mr. Meadows, and Mr. Connolly) introduced the following bill; which was referred to the Committee on Oversight and Government Reform, and in addition to the Committees on Energy and Commerce, Foreign Affairs, the Judiciary, Intelligence (Permanent Select), and Appropriations, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

June 20, 2018

Reported from the Committee on Oversight and Government Reform with an amendment

[Strike out all after the enacting clause and insert the part printed in italic]

June 20, 2018

The Committees on Energy and Commerce, Foreign Affairs, the Judiciary, Intelligence (Permanent Select), and Appropriations discharged; committed to the Committee of the Whole House on the State of the Unionand ordered to be printed

[For text of introduced bill, see copy of bill as introduced on May 23, 2018]

A BILL

To codify provisions relating to the Office of National Drug Control, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Coordinated Response
- 5 through Interagency Strategy and Information Sharing
- 6 Act" or the "CRISIS Act".
- 7 SEC. 2. OFFICE OF NATIONAL DRUG CONTROL.
- 8 (a) Redesignation.—The Office of National Drug
- 9 Control Policy shall be known as the "Office of National
- 10 Drug Control".
- 11 (b) References.—Any reference in any other Federal
- 12 law, Executive order, rule, regulation, or delegation of au-
- 13 thority, or any document of or relating to the Office of Na-
- 14 tional Drug Control Policy is deemed to refer to the Office
- 15 of National Drug Control.
- 16 (c) Codification.—Subtitle I of title 31, United
- 17 States Code, is amended by adding at the end the following
- 18 new chapter:

19 "CHAPTER 10—OFFICE OF NATIONAL

20 **DRUG CONTROL**

"SUBCHAPTER I—OFFICE

[&]quot;Sec.

[&]quot;1001. Definitions.

[&]quot;1002. Office of National Drug Control.

[&]quot;1003. Administration of the office.

[&]quot;1004. National drug control program budget.

[&]quot;1005. National drug control strategy.

[&]quot;1006. Development of an annual national drug control assessment.

[&]quot;1007. Monitoring and evaluation of national drug control program.

[&]quot;1008. Coordination and oversight of the national drug control program.

[&]quot;1009. Emerging threats taskforce, plan, media campaign.

- "1010. National and international coordination.
- "1011. Interdiction.
- "1012. Treatment coordinator.
- "1013. Critical information coordination.
- "1014. Annual audit and investigation requirements.
- "1015. Authorization of appropriations.

"SUBCHAPTER II—HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM

"1021. High intensity drug trafficking areas program.

"SUBCHAPTER III—DRUG-FREE COMMUNITIES SUPPORT PROGRAM

- "1031. Establishment of drug-free communities support program.
- "1032. Program authorization.
- "1033. Information collection and dissemination with respect to grant recipients.
- "1034. Technical assistance and training.
- "1035. Supplemental grants for coalition mentoring activities.
- "1036. Authorization for National Community Antidrug Coalition Institute.
- "1037. Definitions.

1

"1038. Drug-free communities reauthorization.

"SUBCHAPTER I—OFFICE

2 "§ 1001. Definitions

- 3 "In this chapter:
- 4 "(1) AGENCY.—The term 'agency' has the mean-
- 5 ing given the term 'executive agency' in section 102.
- 6 "(2) Appropriate congressional commit-
- 7 TEES.—The term 'appropriate congressional commit-
- 8 tees' means—
- 9 "(A) the Committee on the Judiciary, the
- 10 Committee on Appropriations, and the Caucus
- 11 on International Narcotics Control of the Senate;
- 12 and
- 13 "(B) the Committee on Oversight and Gov-
- 14 ernment Reform, the Committee on the Judici-
- ary, and the Committee on Appropriations of the
- 16 House of Representatives.

1	"(3) DEMAND REDUCTION.—The term 'demand
2	reduction' means any activity conducted by a Na-
3	tional Drug Control Program Agency, other than an
4	enforcement activity, that is intended to reduce or
5	prevent the use of drugs or support or provide treat-
6	ment and recovery efforts, including—
7	"(A) education about the dangers of illicit
8	drug use;
9	"(B) services, programs, or strategies to pre-
10	vent substance use disorder, including evidence-
11	based education campaigns, community-based
12	prevention programs, opioid diversion, collection
13	and disposal of unused prescription drugs, and
14	services to at-risk populations to prevent or
15	delay initial use of an illicit substance;
16	"(C) substance use disorder treatment;
17	"(D) illicit drug use research;
18	$``(E)\ drug\-free\ workplace\ programs;$
19	"(F) drug testing, including the testing of
20	employees;
21	"(G) interventions for illicit drug use and
22	dependence;
23	"(H) expanding availability of access to
24	health care services for the treatment of substance
25	use disorders:

1	"(I) international drug control coordination
2	and cooperation with respect to activities de-
3	scribed in this paragraph;
4	"(J) pre- and post-arrest criminal justice
5	interventions such as diversion programs, drug
6	courts, and the provision of evidence-based treat-
7	ment to individuals with substance use disorders
8	who are arrested or under some form of criminal
9	justice supervision, including medication assisted
10	treatment;
11	"(K) other coordinated and joint initiatives
12	among Federal, State, local, and Tribal agencies
13	to promote comprehensive drug control strategies
14	designed to reduce the demand for, and the avail-
15	ability of, illegal drugs;
16	"(L) international illicit drug use edu-
17	cation, prevention, treatment, recovery, research,
18	rehabilitation activities, and interventions for il-
19	licit drug use and dependence; and
20	"(M) research related to any of the activi-
21	ties described in this paragraph.
22	"(4) Director.—The term 'Director' means the
23	Director of the Office of National Drug Control.

- 1 "(5) DRUG.—The term 'drug' has the meaning 2 given the term 'controlled substance' in section 102(6) 3 of the Controlled Substances Act (21 U.S.C. 802(6)).
 - "(6) DRUG CONTROL.—The term 'drug control'
 means any activity conducted by a National Drug
 Control Program Agency involving supply reduction
 or demand reduction.
 - "(7) EMERGING THREAT.—The term 'emerging threat' means the occurrence of a new and growing trend in the use of an illicit drug or class of drugs, including rapid expansion in the supply of or demand for such drug.
 - "(8) Illicit drug use; illicit drugs; illegal drugs', cillicit drugs', and 'illegal drugs' include the illegal or illicit use of prescription drugs.
 - "(9) LAW ENFORCEMENT.—The term 'law enforcement' or 'drug law enforcement' means all efforts by a Federal, State, local, or Tribal government agency to enforce the drug laws of the United States or any State, including investigation, arrest, prosecution, and incarceration or other punishments or penalties.
 - "(10) National Drug Control Program' means pro-

grams, policies, and activities undertaken by National Drug Control Program Agencies pursuant to the responsibilities of such agencies under the National Drug Control Strategy, including any activities involving supply reduction, demand reduction, or

State, local, and Tribal affairs.

- "(11) National Drug Control Program

 Agency' means any agency (or bureau, office, independent agency, board, division, commission, subdivision, unit, or other component thereof) that is responsible for implementing any aspect of the National Drug Control Strategy, including any agency that receives Federal funds to implement any aspect of the National Drug Control Strategy, but does not include any agency that receives funds for drug control activity solely under the National Intelligence Program or the Military Intelligence Program.
 - "(12) National Drug Control Strategy; Strategy.—The term 'National Drug Control Strategy' or 'Strategy' means the strategy developed and submitted to Congress under section 1005.
 - "(13) Nonprofit organization' means an organization that is described in section 501(c)(3) of the Internal Rev-

1	enue Code of 1986 and exempt from tax under section
2	501(a) of such Code.
3	"(14) Office.—The term 'Office' means the Of-
4	fice of National Drug Control.
5	"(15) State, local, and tribal affairs.—The
6	term 'State, local, and Tribal affairs' means domestic
7	activities conducted by a National Drug Control Pro-
8	gram Agency that are intended to reduce the avail-
9	ability and use of illegal drugs, including—
10	"(A) coordination and enhancement of Fed-
11	eral, State, local, and Tribal law enforcement
12	drug control efforts;
13	"(B) coordination and enhancement of ef-
14	forts among National Drug Control Program
15	Agencies and State, local, and Tribal demand re-
16	duction and supply reduction agencies;
17	"(C) coordination and enhancement of Fed-
18	eral, State, local, and Tribal law enforcement
19	initiatives to gather, analyze, and disseminate
20	information and law enforcement intelligence re-
21	lating to drug control among domestic law en-
22	forcement agencies; and
23	"(D) other coordinated and joint initiatives
24	among Federal, State, local, and Tribal agencies
25	to promote comprehensive drug control strategies

1	designed to reduce the demand for, and the avail-
2	ability of, illegal drugs.
3	"(16) Substance use disorder treatment.—
4	The term 'substance use disorder treatment' means an
5	evidence-based, professionally directed, deliberate, and
6	planned regimen including evaluation, observation,
7	medical monitoring, and rehabilitative services and
8	interventions such as pharmacotherapy, behavioral
9	therapy, and individual and group counseling, on an
10	inpatient or outpatient basis, to help patients with
11	substance use disorder reach recovery.
12	"(17) Supply reduction.—The term 'supply
13	reduction' means any activity or program conducted
14	by a National Drug Control Program Agency that is
15	intended to reduce the availability or use of illegal
16	drugs in the United States or abroad, including—
17	"(A) law enforcement outside the United
18	States;
19	"(B) domestic law enforcement;
20	"(C) source country programs, including
21	economic development programs primarily in-
22	tended to reduce the production or trafficking of
23	illicit drugs;

1	"(D) activities to control international traf-
2	ficking in, and availability of, illegal drugs, in-
3	cluding—
4	"(i) accurate assessment and moni-
5	toring of international drug production and
6	interdiction programs and policies; and
7	"(ii) coordination and promotion of
8	compliance with international treaties re-
9	lating to the production, transportation, or
10	interdiction of illegal drugs;
11	"(E) activities to conduct and promote
12	international law enforcement programs and
13	policies to reduce the supply of drugs;
14	"(F) activities to facilitate and enhance the
15	sharing of domestic and foreign intelligence in-
16	formation among National Drug Control Pro-
17	gram Agencies, relating to the production and
18	trafficking of drugs in the United States and in
19	foreign countries;
20	"(G) activities to prevent the diversion of
21	drugs for their illicit use; and
22	"(H) research related to any of the activi-
23	ties described in this paragraph.

1 "§ 1002. Office of National Drug Control

2	"(a) Establishment of Office.—There is estab-
3	lished in the Executive Office of the President an Office of
4	National Drug Control, which shall—
5	"(1) lead national drug control efforts, including
6	developing and assessing implementation of evidence-
7	based drug control policy;
8	"(2) coordinate and oversee the implementation
9	of the national drug control policy, including the Na-
10	$tional\ Drug\ Control\ Strategy;$
11	"(3) assess and certify the adequacy of National
12	Drug Control Programs and the budget for those pro-
13	grams;
14	"(4) monitor and evaluate the effectiveness of na-
15	tional drug control policy efforts, including the Na-
16	tional Drug Control Program Agencies' programs, by
17	developing and applying specific goals and perform-
18	ance measurements and tracking program-level spend-
19	ing;
20	"(5) identify and respond to emerging threats re-
21	lated to illicit drug use;
22	"(6) administer and evaluate grant programs in
23	furtherance of the National Drug Control Strategy;
24	and
25	"(7) facilitate broad-scale information sharing
26	and data standardization among Federal, State, and

1	local entities to support the national drug control ef-
2	forts.
3	"(b) Director of National Drug Control and
4	Deputy Directors.—
5	"(1) Director.—
6	"(A) In General.—There shall be at the
7	head of the Office a Director who shall hold the
8	same rank and status as the head of an executive
9	department listed in section 101 of title 5,
10	United States Code.
11	"(B) Appointment.—The Director shall be
12	appointed by the President, by and with the ad-
13	vice and consent of the Senate, and shall serve
14	at the pleasure of the President.
15	"(2) Deputy director.—
16	"(A) In general.—There shall be a Dep-
17	uty Director who shall report directly to the Di-
18	rector, be appointed by the President, and serve
19	at the pleasure of the President.
20	"(B) Responsibilities.—The Deputy Di-
21	rector shall—
22	"(i) carry out the responsibilities dele-
23	gated by the Director; and
24	"(ii) be responsible for effectively co-
25	ordinating with the Coordinators.

1	"(c) Responsibilities.—
2	"(1) Policies, goals, objectives, and prior-
3	ITIES.—The Director shall assist the President in di-
4	recting national drug control efforts, including estab-
5	lishing policies, goals, objectives, and priorities for the
6	National Drug Control Program that are based on
7	evidence-based research.
8	"(2) Consultation.—To formulate the National
9	Drug Control policies, goals, objectives, and priorities,
10	the Director—
11	"(A) shall consult with—
12	"(i) State and local governments;
13	"(ii) National Drug Control Program
14	Agencies;
15	"(iii) each committee, working group,
16	council, or other entity established under
17	this chapter, as appropriate;
18	"(iv) the public;
19	"(v) appropriate congressional com-
20	$mittees;\ and$
21	"(vi) any other person in the discretion
22	of the Director; and
23	"(B) may—
24	"(i) establish advisory councils;
25	"(ii) acquire data from agencies; and

1	"(iii) request data from any other enti-
2	ty.
3	"§ 1003. Administration of the office
4	"(a) Employment.—
5	"(1) Authority of the director.—The Direc-
6	tor may select, appoint, employ, and fix compensa-
7	tion of such officers and employees of the Office as
8	may be necessary to carry out the functions of the Of-
9	fice under this chapter.
10	"(2) Prohibitions.—
11	"(A) Generally.—No person shall serve as
12	Director or Deputy Director while serving in
13	any other position in the Federal Government.
14	"(B) Prohibition on political cam-
15	PAIGNING.—Any officer or employee of the Office
16	who is appointed to that position by the Presi-
17	dent, by and with the advice and consent of the
18	Senate, may not participate in Federal election
19	campaign activities, except that such official is
20	not prohibited by this paragraph from making
21	contributions to individual candidates.
22	"(b) Prohibition on the Use of Funds for Polit-
23	ical Campaigns or Ballot Initiatives.—No funds au-
24	thorized under this chapter may be obligated for the purpose

1	of influencing any Federal, State, or local election or ballot
2	initiative.
3	"(c) Personnel Detailed to Office.—
4	"(1) Evaluations.—Notwithstanding any pro-
5	vision of chapter 43 of title 5, the Director shall per-
6	form the evaluation of the performance of any em-
7	ployee detailed to the Office for purposes of the appli-
8	cable performance appraisal system established under
9	such chapter for any rating period, or part thereof,
10	that such employee is detailed to such office.
11	"(2) Compensation.—
12	"(A) Bonus payments.—Subject to the
13	availability of appropriations, the Director may
14	provide periodic bonus payments to any em-
15	ployee detailed to the Office.
16	"(B) Restrictions.—An amount paid
17	under this paragraph to an employee for any pe-
18	riod—
19	"(i) shall not be greater than 20 per-
20	cent of the basic pay paid or payable to
21	such employee for such period; and
22	"(ii) shall be in addition to the basic
23	pay of such employee.
24	"(C) AGGREGATE AMOUNT.—The aggregate
25	amount paid during any fiscal year to an em-

1	ployee detailed to the Office as basic pay,
2	awards, bonuses, and other compensation shall
3	not exceed the annual rate payable at the end of
4	such fiscal year for positions at level III of the
5	Executive Schedule.
6	"(d) Congressional Access to Information.—The
7	location of the Office in the Executive Office of the President
8	shall not be construed as affecting access by Congress, or
9	any committee of the House of Representatives or the Sen-
10	ate, to any—
11	"(1) information, document, or study in the pos-
12	session of, or conducted by or at the direction of the
13	Director; or
14	"(2) personnel of the Office.
15	"(e) Other Authorities of the Director.—In
16	carrying out this chapter, the Director may—
17	"(1) use for administrative purposes, on a reim-
18	bursable basis, the available services, equipment, per-
19	sonnel, and facilities of Federal, State, and local
20	agencies;
21	"(2) procure the services of experts and consult-
22	ants in accordance with section 3109 of title 5 relat-
23	ing to appointments in the Federal Service, at rates
24	of compensation for individuals not to exceed the
25	daily equivalent of the rate of pay payable under level

1	IV of the Executive Schedule under section 5311 of
2	such title; and
3	"(3) use the mails in the same manner as any
4	other agency.
5	"(f) General Services Administration.—The Ad-
6	ministrator of General Services shall provide to the Direc-
7	tor, on a reimbursable basis, such administrative support
8	services as the Director may request.
9	"§ 1004. National drug control program budget
10	"(a) Budget Recommendations.—Not later than
11	July 1 of each year, the Director shall provide to the head
12	of each National Drug Control Program Agency budget rec-
13	ommendations, including requests for specific initiatives
14	that are consistent with the priorities of the President under
15	the National Drug Control Strategy, which shall—
16	"(1) apply to the budget for the next fiscal year
17	scheduled for formulation under chapter 11, and each
18	of the 4 subsequent fiscal years; and
19	"(2) address funding priorities developed in the
20	National Drug Control Strategy.
21	"(b) Responsibilities of National Drug Control
22	Program Agencies.—
23	"(1) In General.—For each fiscal year, the
24	head of each National Drug Control Program Agency
25	shall transmit to the Director a copy of the proposed

- drug control budget request of such agency at the same time as that budget request is submitted to their superiors (and before submission to the Office of Management and Budget) in the preparation of the budget of the President submitted to Congress under section 1105(a).
 - "(2) Submission of drug control budget Requests.—The head of each National Drug Control Program Agency shall ensure timely development and submission to the Director of each proposed drug control budget request transmitted pursuant to this subsection, in such format as may be designated by the Director with the concurrence of the Director of the Office of Management and Budget.
 - "(3) Content of drug control budget request submitted by the head of a National Drug Control Program Agency under this subsection shall include all requests for funds for any drug control activity undertaken by such agency, including demand reduction, supply reduction, and State, local, and Tribal affairs, including any drug law enforcement activities. If an activity has both drug control and nondrug control purposes or applications, such agency shall estimate by a documented calculation the total funds requested for

1	that activity that would be used for drug control, and
2	shall set forth in its request the basis and method for
3	making the estimate.
4	"(c) Review and Certification of Budget Re-
5	QUESTS AND BUDGET SUBMISSIONS OF NATIONAL DRUG
6	Control Program Agencies.—
7	"(1) In general.—The Director shall review
8	each drug control budget request submitted to the Di-
9	rector under subsection (b).
10	"(2) Review of budget requests.—
11	"(A) Inadequate requests.—If the Di-
12	rector concludes that a budget request submitted
13	under subsection (b) is inadequate, in whole or
14	in part, to implement the objectives of the Na-
15	tional Drug Control Strategy with respect to the
16	agency or program at issue for the year for
17	which the request is submitted, the Director shall
18	submit to the head of the applicable National
19	Drug Control Program Agency a written de-
20	scription identifying the funding levels and spe-
21	cific initiatives that would, in the determination
22	of the Director, make the request adequate to im-
23	plement those objectives.
24	"(B) ADEQUATE REQUESTS.—If the Direc-
25	tor concludes that a budget request submitted

1	under subsection (b) is adequate to implement
2	the objectives of the National Drug Control
3	Strategy with respect to the agency or program
4	at issue for the year for which the request is sub-
5	mitted, the Director shall submit to the head of
6	the applicable National Drug Control Program
7	Agency a written statement confirming the ade-
8	quacy of the request.
9	"(C) Record.—The Director shall main-
10	tain a record of each description submitted
11	under subparagraph (A) and each statement sub-
12	mitted under subparagraph (B).
13	"(3) Specific requests.—The Director shall
14	not confirm the adequacy of any budget request that
15	requests a level of funding that will not enable
16	achievement of the goals of the National Drug Control
17	Strategy, including—
18	"(A) requests funding for Federal law en-
19	forcement activities that do not adequately com-
20	pensate for transfers of drug enforcement re-
21	sources and personnel to law enforcement and
22	$investigation\ activities;$
23	"(B) requests funding for law enforcement
24	activities on the borders of the United States that

1	do not adequately direct resources to drug inter-
2	diction and enforcement;
3	"(C) requests funding for drug treatment
4	activities that do not provide adequate results
5	and accountability measures;
6	"(D) requests funding for drug treatment
7	activities that do not adequately support and en-
8	hance Federal drug treatment programs and ca-
9	pacity; and
10	"(E) requests funding for the operations
11	and management of the Department of Home-
12	land Security that does not include a specific re-
13	quest for funds for the Office of Counternarcotics
14	Enforcement to carry out its responsibilities
15	under section 878 of the Homeland Security Act
16	of 2002 (6 U.S.C. 458).
17	"(4) AGENCY RESPONSE.—
18	"(A) In general.—The head of a National
19	Drug Control Program Agency that receives a
20	description under paragraph (2)(A) shall include
21	the funding levels and initiatives described by
22	the Director in the budget submission for that
23	agency to the Office of Management and Budget.
24	"(B) Impact statement.—The head of a
25	National Drug Control Program Agency that has

1	altered its budget submission under this para-
2	graph shall include as an appendix to the budget
3	submission for that agency to the Office of Man-
4	agement and Budget an impact statement that
5	summarizes—
6	"(i) the changes made to the budget
7	under this paragraph; and
8	"(ii) the impact of those changes on the
9	ability of that agency to perform its other
10	responsibilities, including any impact on
11	specific missions or programs of the agency.
12	"(C) Congressional notification.—The
13	head of a National Drug Control Program Agen-
14	cy shall submit a copy of any impact statement
15	under subparagraph (B) to the Senate, the
16	House of Representatives, and the appropriate
17	congressional committees, at the time the budget
18	for that agency is submitted to Congress under
19	section $1105(a)$.
20	"(5) Certification of budget submis-
21	SIONS.—
22	"(A) In general.—At the time a National
23	Drug Control Program Agency submits its budg-
24	et request to the Office of Management and
25	Budget, the head of the National Drug Control

1	Program Agency shall submit a copy of the
2	budget request to the Director.
3	"(B) Review and Certification of Sub-
4	MISSIONS.—The Director shall review each budg-
5	et submission submitted under subparagraph (A)
6	and submit to the appropriate congressional
7	committees one of the following:
8	"(i) A written certification of the budg-
9	et request for the agency indicating such re-
10	quest fully funds the National Drug Control
11	Programs as necessary to achieve the goals
12	of the National Drug Control Strategy, in-
13	cluding a written statement explaining the
14	basis for the determination that the budget
15	provides sufficient resources for the agency
16	to achieve the goals of the Strategy.
17	"(ii) A written certification of the
18	budget request for the agency indicating
19	such request partially funds the National
20	Drug Control Programs as necessary to
21	achieve the goals of the Strategy, including
22	a written statement explaining the basis for
23	the determination and identifying the level
24	of funding sufficient to achieve the goals of
25	$the\ Strategy.$

1 "(iii) A written decertification of the 2 budget request for the agency indicating the Director is unable to determine whether 3 4 such budget request for the agency fully 5 funds or partially funds the National Drug 6 Control Programs as necessary to achieve 7 the goals of the National Drug Control 8 Strategy, including a written statement 9 identifying the additional information necessary for the Director to make a deter-10 11 mination on such budget and the level of 12 funding sufficient to achieve the goals of the 13 Strategy. 14 "(iv) A written decertification of the 15 budget request for the agency indicating 16 that such budget is insufficient to fund the 17 National Drug Control Programs as nec-18 essary to achieve the goals of the Strategy, 19 including a written statement explaining 20 the basis for the determination that the 21 budget is insufficient and identifying the 22 level of funding sufficient to achieve the 23 goals of the Strategy. 24 "(d) National Drug Control Program Budget

Proposal.—For each fiscal year, following the trans-

- mission of proposed drug control budget requests to the Di rector under subsection (b), the Director shall, in consulta tion with the head of each National Drug Control Program
- 4 Agency and the head of each major national organization
- 5 that represents law enforcement officers, agencies, or asso-
- 6 ciations—

17

18

19

20

21

22

23

24

25

7 "(1) develop a consolidated National Drug Con-8 trol Program budget proposal designed to implement 9 the National Drug Control Strategy and to inform Congress and the public about the total amount pro-10 11 posed to be spent on all supply reduction, demand re-12 duction, State, local, and Tribal affairs, including 13 any drug law enforcement, and other drug control ac-14 tivities by the Federal Government, which shall con-15 form to the content requirements set forth in sub-16 section (b)(3) and include—

"(A) for each National Drug Control Program Agency, a list of whether the funding level is full, partial, or insufficient to achieve the goals of the National Drug Control Strategy or whether the Director is unable to determine whether the budget request for the agency fully funds or partially funds the agency's activities and contributions as necessary to achieve the goals of National Drug Control Strategy;

1	"(B) a statement describing the extent to
2	which any budget of a National Drug Control
3	Program Agency with less than full funding
4	hinders progress on achieving the goals of the
5	National Drug Control Strategy; and
6	"(C) alternative funding structures that
7	could improve progress on achieving the goals of
8	the National Drug Control Strategy; and
9	"(2) submit the consolidated budget proposal to
10	the President and Congress.
11	"(e) Budget Estimate or Request Submission to
12	Congress.—Whenever the Director submits any budget es-
13	timate or request to the President or the Office of Manage-
14	ment and Budget, the Director shall concurrently transmit
15	copies of that estimate or request to the appropriate congres-
16	$sional\ committees.$
17	"(f) Reprogramming and Transfer Requests.—
18	"(1) In general.—No National Drug Control
19	Program Agency shall submit to Congress a re-
20	programming or transfer request with respect to any
21	amount of appropriated funds in an amount exceed-
22	ing \$1,000,000 that is included in the National Drug
23	Control Program budget unless the request has been
24	approved by the Director. If the Director has not re-
25	sponded to a request for reprogramming subject to

this paragraph within 30 days after receiving notice 1 2 of the request having been made, the request shall be deemed approved by the Director under this para-3 4 graph and forwarded to Congress. "(2) APPEAL.—The head of any National Drug 5 6 Control Program Agency may appeal to the President 7 any disapproval by the Director of a reprogramming 8 or transfer request under this subsection. 9 "§ 1005. National drug control strategy 10 "(a) In General.— 11 "(1) Statement of drug policy prior-12 ITIES.—The Director shall release a statement of drug 13 policy priorities in the calendar year of a Presi-14 dential inauguration following the inauguration but 15 not later than April 1. "(2) National drug control strategy sub-16 17 MITTED BY THE PRESIDENT.—Not later than the first 18 Monday in February following the year in which the 19 term of the President commences, the President shall 20 submit to Congress a National Drug Control Strat-21 egy. 22 "(b) Development of the National Drug Con-23 TROL STRATEGY.— "(1) Promulgation.—The Director shall pro-24

mulgate the National Drug Control Strategy, which

1	shall set forth a comprehensive plan to reduce illicit
2	drug use and the consequences of such illicit drug use
3	in the United States by limiting the availability of
4	and reducing the demand for illegal drugs and pro-
5	moting prevention, early intervention, treatment, and
6	recovery support for individuals with substance use
7	disorders.
8	"(2) State and local commitment.—The Di-
9	rector shall seek the support and commitment of
10	State, local, and Tribal officials in the formulation
11	and implementation of the National Drug Control
12	Strategy.
13	"(3) Strategy based on evidence.—The Di-
14	rector shall ensure the National Drug Control Strat-
15	egy is based on the best available medical and sci-
16	entific evidence regarding the policies that are most
17	effective in reducing the demand for and supply of il-
18	legal drugs.
19	"(4) Process for development and submis-
20	SION OF NATIONAL DRUG CONTROL STRATEGY.—In
21	developing and effectively implementing the National
22	Drug Control Strategy, the Director—
23	"(A) shall consult with—
24	"(i) the heads of the National Drug
25	Control Program Agencies;

1	"(ii) the United States Interdiction
2	Coordinator;
3	$``(iii)\ the\ Interdiction\ Committee;$
4	"(iv) the appropriate congressional
5	committees and any other committee of ju-
6	risdiction;
7	"(v) State, local, and Tribal officials;
8	"(vi) private citizens and organiza-
9	tions, including community and faith-based
10	organizations, with experience and expertise
11	in demand reduction;
12	"(vii) private citizens and organiza-
13	tions with experience and expertise in sup-
14	ply reduction; and
15	"(viii) appropriate representatives of
16	foreign governments; and
17	"(B) in satisfying the requirements of sub-
18	paragraph (A), shall ensure, to the maximum ex-
19	tent possible, that State, local, and Tribal offi-
20	cials and relevant private organizations commit
21	to support and take steps to achieve the goals
22	and objectives of the National Drug Control
23	Strategy.
24	"(c) Contents of the National Drug Control
25	Strategy.—

1	"(1) In General.—The National Drug Control
2	Strategy submitted under subsection (a)(2) shall in-
3	clude the following:
4	"(A) A description of the current prevalence
5	of illicit drug use in the United States, including
6	both the availability of illicit drugs and the
7	prevalence of substance use disorders, which shall
8	include the following:
9	"(i) Such description for the previous
10	three years for any drug identified as an
11	emerging threat under section 1009 and
12	any other illicit drug identified by the Di-
13	rector as having a significant impact on the
14	prevalence of illicit drug use.
15	"(ii) A summary of the data and
16	trends presented in the Drug Control Data
17	Dashboard required under section 1013.
18	"(B) A mission statement detailing the
19	major functions of the National Drug Control
20	Program.
21	"(C) A list of comprehensive, research-based,
22	long-range, quantifiable goals for reducing illicit
23	drug use, including—

1	"(i) the percentage of the total flow of
2	illicit drugs to be interdicted during the
3	time period covered by the Strategy; and
4	"(ii) the number of individuals to re-
5	ceive treatment for substance use disorders.
6	"(D) A description of how each goal listed
7	in the National Drug Control Strategy will be
8	achieved, including—
9	"(i) a list of relevant National Drug
10	Control Program Agencies and each such
11	agency's related programs, activities, and
12	available assets and the role of each such
13	program, activity, and asset in achieving
14	$the\ goal;$
15	"(ii) a list of relevant stakeholders and
16	each such stakeholder's role in achieving the
17	goal;
18	"(iii) an estimate of Federal funding
19	and other resources needed to achieve each
20	goal;
21	"(iv) an identification of existing or
22	new coordinating mechanisms needed to
23	achieve the goal; and
24	"(v) a description of the Office's role in
25	facilitating the achievement of such goal.

1	"(E) For each year covered by the Strategy,
2	a performance evaluation plan for each goal list-
3	ed in the National Drug Control Strategy for
4	each National Drug Control Program Agency,
5	including—
6	"(i) specific performance measures for
7	each National Drug Control Program Agen-
8	cy and each such agency's related programs
9	and activities;
10	"(ii) annual and quarterly objectives
11	and targets for each performance measure;
12	and
13	"(iii) an estimate of Federal funding
14	and other resources needed to achieve each
15	performance measure.
16	"(F) A list identifying existing data sources
17	or a description of data collection needed to
18	evaluate performance, including a description of
19	how the Director will obtain such data.
20	"(G) A list of anticipated challenges to
21	achieving the National Drug Control Strategy
22	goals and planned actions to address such chal-
23	lenges;
24	"(H) A description of how each goal was de-
25	termined, including—

1	"(i) a description of each required con-
2	sultation and how such consultation was in-
3	corporated;
4	"(ii) data, research, or other informa-
5	tion used to inform the decision; and
6	"(iii) a statement of whether the goal
7	established in subparagraph (C)(i) will be
8	adequate to disrupt drug trafficking organi-
9	zations that supply the majority of foreign-
10	sourced illicit drugs trafficked into the
11	United States.
12	"(I) A 5-year projection for program and
13	budget priorities.
14	"(J) A review of international, State, local,
15	and private sector drug control activities to en-
16	sure that the United States pursues coordinated
17	and effective drug control at all levels of govern-
18	ment.
19	"(K) Such statistical data and information
20	as the Director considers appropriate to dem-
21	onstrate and assess trends relating to illicit drug
22	use, the effects and consequences of illicit drug
23	use (including the effects on children), supply re-
24	duction, demand reduction, drug-related law en-

1	forcement, and the implementation of the Na-
2	tional Drug Control Strategy.
3	"(2) Additional strategies.—
4	"(A) In general.—The Director shall in-
5	clude in the National Drug Control Strategy the
6	additional strategies required under this para-
7	graph and shall comply with the following:
8	"(i) Provide a copy of the additional
9	strategies to the appropriate congressional
10	committees and to the Committee on Armed
11	Services and the Committee on Homeland
12	Security of the House of Representatives,
13	and the Committee on Homeland Security
14	and Governmental Affairs and the Com-
15	mittee on Armed Services of the Senate.
16	"(ii) Issue the additional strategies in
17	consultation with the head of each relevant
18	National Drug Control Program Agency
19	and any relevant official of a State, local or
20	Tribal government, and the government of
21	$other\ countries.$
22	"(iii) Not change any existing agency
23	authority or construe any strategy described
24	under this paragraph to amend or modify
25	any law governing interagency relationship

1	but may include recommendations about
2	changes to such authority or law.
3	"(iv) Present separately from the rest
4	of any strategy described under this para-
5	graph any information classified under cri-
6	teria established by an Executive order, or
7	whose public disclosure, as determined by
8	the Director or the head of any relevant Na-
9	tional Drug Control Program Agency,
10	would be detrimental to the law enforcement
11	or national security activities of any Fed-
12	eral, State, local, or Tribal agency.
13	"(B) Requirement for southwest bor-
14	DER COUNTERNARCOTICS.—
15	"(i) Purposes.—The Southwest Bor-
16	der Counternarcotics Strategy shall—
17	"(I) set forth the Government's
18	strategy for preventing the illegal traf-
19	ficking of drugs across the inter-
20	national border between the United
21	States and Mexico, including through
22	ports of entry and between ports of
23	entry on that border;
24	"(II) state the specific roles and
25	responsibilities of the relevant National

1	Drug Control Program Agencies for
2	implementing that strategy; and
3	"(III) identify the specific re-
4	sources required to enable the relevant
5	National Drug Control Program Agen-
6	cies to implement that strategy.
7	"(ii) Specific content related to
8	DRUG TUNNELS BETWEEN THE UNITED
9	STATES AND MEXICO.—The Southwest Bor-
10	der Counternarcotics Strategy shall in-
11	clude—
12	"(I) a strategy to end the con-
13	struction and use of tunnels and sub-
14	terranean passages that cross the inter-
15	national border between the United
16	States and Mexico for the purpose of il-
17	legal trafficking of drugs across such
18	border; and
19	"(II) recommendations for crimi-
20	nal penalties for persons who construct
21	or use such a tunnel or subterranean
22	passage for such a purpose.
23	"(C) Requirement for northern bor-
24	DER COUNTERNARCOTICS STRATEGY —

1	"(i) Purposes.—The Northern Border
2	Counternarcotics Strategy shall—
3	"(I) set forth the strategy of the
4	Federal Government for preventing the
5	illegal trafficking of drugs across the
6	international border between the
7	United States and Canada, including
8	through ports of entry and between
9	ports of entry on the border;
10	"(II) state the specific roles and
11	responsibilities of each relevant Na-
12	tional Drug Control Program Agency
13	$for \ implementing \ the \ strategy;$
14	"(III) identify the specific re-
15	sources required to enable the relevant
16	National Drug Control Program Agen-
17	cies to implement the strategy;
18	"(IV) be designed to promote, and
19	not hinder, legitimate trade and travel;
20	and
21	"(V) reflect the unique nature of
22	small communities along the inter-
23	national border between the United
24	States and Canada, ongoing coopera-
25	tion and coordination with Canadian

1	law, enforcement authorities, and vari-
2	ations in the volumes of vehicles and
3	pedestrians crossing through ports of
4	entry along the international border
5	between the United States and Canada.
6	"(ii) Specific content related to
7	CROSS-BORDER INDIAN RESERVATIONS.—
8	The Northern Border Counternarcotics
9	Strategy shall include—
10	"(I) a strategy to end the illegal
11	trafficking of drugs to or through In-
12	dian reservations on or near the inter-
13	national border between the United
14	States and Canada; and
15	"(II) recommendations for addi-
16	tional assistance, if any, needed by
17	Tribal law enforcement agencies relat-
18	ing to the strategy, including an eval-
19	uation of Federal technical and finan-
20	cial assistance, infrastructure capacity
21	building, and interoperability defi-
22	ciencies.
23	"(3) Classified information.—Any contents
24	of the National Drug Control Strategy that involve
25	information properly classified under criteria estab-

1	lished by an Executive order shall be presented to
2	Congress separately from the rest of the National
3	Drug Control Strategy.
4	"(4) Selection of data and information.—
5	In selecting data and information for inclusion under
6	paragraph (1), the Director shall ensure—
7	"(A) the inclusion of data and information
8	that will permit analysis of current trends
9	against previously compiled data and informa-
10	tion where the Director believes such analysis en-
11	hances long-term assessment of the National
12	Drug Control Strategy; and
13	"(B) the inclusion of data and information
14	to permit a standardized and uniform assess-
15	ment of the effectiveness of drug treatment pro-
16	grams in the United States.
17	"(d) Annual Performance Supplement.—Not later
18	than the first Monday in February of each year following
19	the year in which the National Drug Control Strategy is
20	submitted pursuant to subsection (a)(2), the Director shall
21	submit to the appropriate congressional committees a sup-
22	plement to the Strategy that shall include—
23	"(1) annual and quarterly quantifiable and
24	measurable objectives and specific targets to accom-

1	plish long-term quantifiable goals specified in the
2	Strategy; and
3	"(2) for each year covered by the Strategy, a per-
4	formance evaluation plan for each goal listed in the
5	Strategy for each National Drug Control Program
6	Agency, including—
7	"(A) specific performance measures for each
8	National Drug Control Program Agency and
9	each such agency's related programs and activi-
10	ties;
11	"(B) annual and quarterly objectives and
12	targets for each performance measure; and
13	"(C) an estimate of Federal funding and
14	other resources needed to achieve each perform-
15	ance measure.
16	"(e) Submission of Revised Strategy.—The Presi-
17	dent may submit to Congress a revised National Drug Con-
18	trol Strategy that meets the requirements of this section—
19	"(1) at any time, upon a determination of the
20	President, in consultation with the Director, that the
21	National Drug Control Strategy in effect is not suffi-
22	ciently effective; or
23	"(2) if a new President or Director takes office.
24	"(f) Failure of President to Submit National
25	Drug Control Strategy.—If the President does not sub-

- 1 mit a National Drug Control Strategy to Congress in ac-
- 2 cordance with subsection (a)(2), not later than five days
- 3 after the first Monday in February following the year in
- 4 which the term of the President commences, the President
- 5 shall send a notification to the appropriate congressional
- 6 committees—
- 7 "(1) explaining why the Strategy was not sub-
- 8 mitted; and
- 9 "(2) specifying the date by which the Strategy
- 10 will be submitted.
- 11 "§ 1006. Development of an annual national drug con-
- 12 trol assessment
- 13 "(a) Timing.—Not later than the first Monday in Feb-
- 14 ruary of each year, the Director shall submit to the Presi-
- 15 dent, Congress, and the appropriate congressional commit-
- 16 tees, a report assessing the progress of each National Drug
- 17 Control Program Agency toward achieving the annual
- 18 goals, objectives, and targets contained in the National
- 19 Drug Control Strategy applicable to the prior fiscal year.
- 20 "(b) Process for Development of the Annual
- 21 Assessment.—Not later than November 1 of each year, the
- 22 head of each National Drug Control Program Agency shall
- 23 submit, in accordance with guidance issued by the Director,
- 24 to the Director an evaluation of progress by the agency with
- 25 respect to drug control program goals using the performance

1	measures for the agency developed under this section, in-
2	cluding progress with respect to—
3	"(1) success in achieving the goals of the Na-
4	$tional\ Drug\ Control\ Strategy;$
5	"(2) success in reducing domestic and foreign
6	sources of illegal drugs;
7	"(3) success in expanding access to and increas-
8	ing the effectiveness of substance use disorder treat-
9	ment;
10	"(4) success in protecting the borders of the
11	United States (and in particular the Southwestern
12	border of the United States) from penetration by ille-
13	gal narcotics;
14	"(5) success in reducing crime associated with
15	drug use in the United States;
16	"(6) success in reducing the negative health and
17	social consequences of drug use in the United States;
18	and
19	"(7) implementation of drug treatment and pre-
20	vention programs in the United States and improve-
21	ments in the adequacy and effectiveness of such pro-
22	grams.
23	"(c) Contents of the Annual Assessment.—The
24	Director shall include in the annual assessment required
25	under subsection (a)—

- 1 "(1) a summary of each evaluation received by 2 the Director under subsection (b);
- 3 "(2) a summary of the progress of each National 4 Drug Control Program Agency toward the drug con-5 trol program goals of the agency using the perform-6 ance measures for the agency developed under this sec-7 tion;
 - "(3) an assessment of the effectiveness of each
 Drug Control Program agency and program in
 achieving the National Drug Control Strategy for the
 previous year, including a specific evaluation of
 whether the applicable goals, measures, objectives, and
 targets for the previous year were met;
 - "(4) for National Drug Control Program Agencies that administer grant programs, an evaluation of the effectiveness of each grant program, including an accounting of the funds disbursed by the program in the prior year and a summary of how those funds were used by the grantees and sub-grantees during that period;
 - "(5) a detailed accounting of the amount of funds obligated by each National Drug Control Program Agency in carrying out the responsibilities of that agency under the Strategy, including the infor-

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

1	mation submitted to the Director under section
2	1007(b);
3	"(6) an assessment of the effectiveness of any
4	Emerging Threat Response Plan in effect for the pre-
5	vious year, including a specific evaluation of whether
6	the objectives and targets were met and reasons for the
7	success or failure of the previous year's plan;
8	"(7) a detailed accounting of the amount of
9	funds obligated during the previous fiscal year for
10	carrying out the media campaign under section
11	1009(d), including each recipient of funds, the pur-
12	pose of each expenditure, the amount of each expendi-
13	ture, any available outcome information, and any
14	other information necessary to provide a complete ac-
15	counting of the funds expended; and
16	"(8) the assessments required under this sub-
17	section shall be based on the Performance Measure-
18	ment System describe in subsection (d).
19	"(d) Performance Measurement System.—The
20	Director shall include in the annual assessment required
21	under subsection (a) a national drug control performance
22	measurement system, that—
23	"(1) develops annual, 2-year, and 5-year per-
24	formance measures, objectives, and targets for each

National Drug Control Strategy goal and objective es-

1	tablished for reducing drug use, availability, and the
2	consequences of drug use;
3	"(2) describes the sources of information and
4	data that will be used for each performance measure
5	incorporated into the performance measurement sys-
6	tem;
7	"(3) identifies major programs and activities of
8	the National Drug Control Program Agencies that
9	support the goals and annual objectives of the Na-
10	$tional\ Drug\ Control\ Strategy;$
11	"(4) evaluates the contribution of demand reduc-
12	tion and supply reduction activities implemented by
13	each National Drug Control Program Agency in sup-
14	port of the National Drug Control Strategy;
15	"(5) monitors consistency between the drug-re-
16	lated goals, measures, targets, and objectives of the
17	National Drug Control Program Agencies and ensures
18	that each agency's goals and budgets support, and are
19	fully consistent with, the National Drug Control
20	Strategy; and
21	"(6) coordinates the development and implemen-
22	tation of national drug control data collection and re-
23	porting systems to support policy formulation and
24	performance measurement, including an assessment

of-

"(A) the quality of current drug use meas-
urement instruments and techniques to measure
supply reduction and demand reduction activi-
ties;
"(B) the adequacy of the coverage of exist-
ing national drug use measurement instruments
and techniques to measure the illicit drug user
population, and groups that are at risk for illicit
drug use;
"(C) the adequacy of the coverage of existing
national treatment outcome monitoring systems
to measure the effectiveness of substance use dis-
order treatment in reducing illicit drug use and
criminal behavior during and after the comple-
tion of substance use disorder treatment; and
"(D) the actions the Director shall take to
correct any deficiencies and limitations identi-
fied pursuant to subparagraphs (A), (B), and
(C).
"(e) Modifications.—A description of any modifica-
tions made during the preceding year to the national drug
performance measurement system described in subsection
(d) shall be included in each report submitted under sub-

24 section (a).

1	"(f) Annual Report on Consultation.—The Direc-
2	tor shall include in the annual assessment required under
3	subsection (a)—
4	"(1) a detailed description of how the Office has
5	consulted with and assisted State, local, and Tribal
6	governments with respect to the formulation and im-
7	plementation of the National Drug Control Strategy
8	and other relevant issues; and
9	"(2) a general review of the status of, and trends
10	in, demand reduction activities by private sector enti-
11	ties and community-based organizations, including
12	faith-based organizations, to determine their effective-
13	ness and the extent of cooperation, coordination, and
14	mutual support between such entities and organiza-
15	tions and Federal, State, local, and Tribal govern-
16	ment agencies.
17	"(g) Performance-budget Coordinator.—
18	"(1) Designation.—The Director shall des-
19	ignate or appoint a United States Performance-Budg-
20	et Coordinator to—
21	"(A) ensure the Director has sufficient in-
22	formation about the performance of each Na-
23	tional Drug Control Program Agency, the im-
24	pact Federal funding has had on the goals in the
25	Strategy, and the likely contributions to the

1	goals of the Strategy based on funding levels of
2	each National Drug Control Program Agency, to
3	make an independent assessment of the budget
4	request of each agency under section 1004;
5	"(B) advise the Director on agency budgets,
6	performance measures and targets, and addi-
7	tional data and research needed to make in-
8	formed policy decisions in the National Drug
9	Control Budget and Strategy; and
10	"(C) other duties as may be determined by
11	the Director with respect to measuring or assess-
12	ing performance or agency budgets.
13	"(2) Determination of Position.—The Direc-
14	tor shall determine whether the coordinator position
15	is a career or noncareer position in the Senior Execu-
16	$tive\ Service.$
17	"§ 1007. Monitoring and evaluation of national drug
18	control program
19	"(a) In General.—The Director shall monitor imple-
20	mentation of the National Drug Control Program and the
21	activities of the National Drug Control Program Agencies
22	in carrying out the goals and objectives of the National
23	Drug Control Strategy including—
24	"(1) conducting program and performance au-
25	dits and evaluations; and

- 1 "(2) requesting assistance from the Inspector
- 2 General of the relevant agency in such audits and
- *evaluations.*
- 4 "(b) Accounting of Funds Expended.—Not later
- 5 than December 1 of each year and in accordance with guid-
- 6 ance issued by the Director, the head of each National Drug
- 7 Control Program Agency shall submit to the Director a de-
- 8 tailed accounting of all funds expended by the agency for
- 9 National Drug Control Program activities during the pre-
- 10 vious fiscal year and shall ensure such detailed accounting
- 11 is authenticated by the Inspector General for such agency
- 12 prior to submission to the Director.
- 13 "(c) Notification.—The Director shall notify any
- 14 National Drug Control Program Agency if its activities are
- 15 not in compliance with the responsibilities of the agency
- 16 under the National Drug Control Strategy, transmit a copy
- 17 of each such notification to the President and the appro-
- 18 priate congressional committees, and maintain a copy of
- 19 each such notification.
- 20 "(d) Recommendations.—The Director shall make
- 21 such recommendations to the President and the appropriate
- 22 congressional committees as the Director determines are ap-
- 23 propriate regarding changes in the organization, manage-
- 24 ment, and budgets of the National Drug Control Program
- 25 Agencies, and changes in the allocation of personnel to and

1	within those agencies, to implement the policies, goals, pri-
2	orities, and objectives established under section $1002(c)(1)$
3	and the National Drug Control Strategy.
4	"(e) Authorization, Development, and Implemen-
5	TATION OF A COORDINATED TRACKING SYSTEM.—
6	"(1) Establishment.—The Director, shall es-
7	tablish a coordinated tracking system of federally-
8	funded initiatives and grant programs which shall—
9	"(A) be the central repository of all relevant
10	grants;
11	"(B) identify duplication, overlap, or gaps
12	in funding to provide increased accountability of
13	federally-funded grants for substance abuse treat-
14	ment, prevention, and enforcement;
15	"(C) identify impediments that applicants
16	currently have in the grant application process
17	with applicable agencies; and
18	"(D) be developed and maintained by the
19	Office with the support of designated National
20	Drug Control Program Agencies, and any other
21	agency determined by the Director.
22	"(2) Performance metrics.—The Director
23	shall identify metrics and achievable goals for grant
24	recipients in furtherance of the Strategy. Such
25	metrics should be used to measure how effective each

- federally funded initiative is in achieving the objectives of the Strategy and to enable comparisons of federally funded initiatives to identify those that are the most cost effective.
 - "(3) Grant application standardization.—
 The Director, in consultation with the head of each National Drug Control Program Agency, shall develop a plan for coordinating and standardizing drug control grant application processes and develop a joint application to be used by all National Drug Control Program Agencies to reduce the administrative burden and improve oversight of Federal funds.
 - "(4) CENTRAL PORTAL.—The Director shall maintain on the public, electronic portal of the Office a list all drug control grant award opportunities available in a central location. The head of each National Drug Control Program Agency shall provide a complete list of all drug control program grant award opportunities to the Director and annually update such list.
 - "(5) Report to congress.—The Director shall include in the assessment submitted to Congress under section 1006 an assessment on progress under this section and the feasibility of block grants of Federal funding to States.

1	"§ 1008. Coordination and oversight of the national
2	drug control program
3	"(a) In General.—The Director shall coordinate and
4	oversee the implementation by the National Drug Control
5	Program Agencies of the policies, goals, objectives, and pri-
6	orities established under section 1002(c)(1) and the fulfill-
7	ment of the responsibilities of such agencies under the Na-
8	tional Drug Control Strategy and make recommendations
9	to National Drug Control Program Agency heads with re-
10	spect to implementation of National Drug Control Pro-
11	grams.
12	"(b) Detailing Employees to Other Agencies.—
13	"(1) REQUEST.—The Director may request the
14	head of an agency or program of the Federal Govern-
15	ment to place agency personnel who are engaged in
16	drug control activities on temporary detail to another
17	agency in order to implement the National Drug Con-
18	$trol\ Strategy.$
19	"(2) AGENCY COMPLIANCE.—The head of the
20	agency shall comply with such a request.
21	"(3) Maximum number of detailees.—The
22	maximum number of personnel who may be detailed
23	to another agency (including the Office) under this
24	subsection during any fiscal year is—
25	"(A) for the Department of Defense, 50; and
26	"(B) for any other agency, 10.

1	"(c) Directing Federal Funding.—The Director
2	may transfer funds made available to a National Drug
3	Control Program Agency for National Drug Control Strat-
4	egy programs and activities to another account within such
5	agency or to another National Drug Control Program Agen-
6	cy for National Drug Control Strategy programs and ac-
7	tivities, except that—
8	"(1) the authority under this subsection may be
9	limited in an annual appropriations Act or other
10	provision of Federal law;
11	"(2) the Director may exercise the authority
12	under this subsection only with the concurrence of the
13	head of each affected agency;
14	"(3) in the case of an interagency transfer, the
15	total amount of transfers under this subsection may
16	not exceed 3 percent of the total amount of funds
17	made available for National Drug Control Strategy
18	programs and activities to the agency from which
19	those funds are to be transferred;
20	"(4) funds transferred to an agency under this
21	subsection may only be used to increase the funding
22	for programs or activities authorized by law;
23	"(5) the Director shall—
24	"(A) submit to the appropriate congres-
25	sional committees and any other applicable com-

1	mittees of jurisdiction, a reprogramming or
2	transfer request in advance of any transfer under
3	this subsection in accordance with the regula-
4	tions of the affected agency or agencies; and
5	"(B) annually submit to the appropriate
6	congressional committees a report describing the
7	effect of all transfers of funds made pursuant to
8	this subsection or section 1004(f) during the 12-
9	month period preceding the date on which the re-
10	port is submitted; and
11	"(6) funds may only be used for—
12	"(A) expansion of demand reduction activi-
13	ties;
14	"(B) interdiction of illicit drugs on the high
15	seas, in United States territorial waters, and at
16	United States ports of entry by officers and em-
17	ployees of Drug Control Program Agencies and
18	domestic and foreign law enforcement officers;
19	"(C) accurate assessment and monitoring of
20	international drug production and interdiction
21	programs and policies;
22	"(D) activities to facilitate and enhance the
23	sharing of domestic and foreign intelligence in-
24	formation among Drug Control Program Agen-
25	cies related to the production and trafficking of

1	drugs in the United States and foreign countries;
2	and
3	"(E) activities to prevent the diversion of
4	prescription drugs for illicit use and research re-
5	lated to any of these activities.
6	"(d) Directing Federal Funding to Respond to
7	Emerging Threats.—
8	"(1) In general.—The Director may transfer
9	funds made available to a National Drug Control
10	Program Agency for National Drug Control Strategy
11	programs and activities to another account within
12	such agency or to another National Drug Control
13	Program Agency for National Drug Control Strategy
14	programs and activities to implement the provisions
15	of a plan developed under section 1009, except that—
16	"(A) the authority under this subsection
17	may be limited in an annual appropriations Act
18	or other provision of Federal law;
19	"(B) in the case of an interagency transfer,
20	the total amount of transfers under this sub-
21	section may not exceed 10 percent of the total
22	amount of funds made available for National
23	Drug Control Strategy programs and activities
24	to the agency from which those funds are to be
25	transferred:

1	"(C) funds transferred to an agency under
2	this subsection may only be used to increase the
3	funding for programs or activities authorized by
4	law;
5	"(D) no transfer of funds under this sub-
6	section may result in a reduction in total Fed-
7	eral expenditures for substance use disorder
8	treatment;
9	"(E) the Director shall—
10	"(i) submit to the appropriate congres-
11	sional committees and any other applicable
12	committees of jurisdiction, a reprogram-
13	ming or transfer request in advance of any
14	transfer under this subsection in accordance
15	with the regulations of each affected agency,
16	and
17	"(ii) annually submit to the appro-
18	priate congressional committees a report de-
19	scribing the effect of all transfers of funds
20	made pursuant to this subsection or section
21	1004(f) during the 12-month period pre-
22	ceding the date on which the report is sub-
23	$mitted;\ and$
24	"(F) funds may only be used for—

1	"(i) expansion of demand reduction ac-
2	tivities;
3	"(ii) interdiction of illicit drugs on the
4	high seas, in United States territorial
5	waters, and at United States ports of entry
6	by officers and employees of Drug Control
7	Program agencies and domestic and foreign
8	law enforcement officers;
9	"(iii) accurate assessment and moni-
10	toring of international drug production and
11	interdiction programs and policies;
12	"(iv) activities to facilitate and en-
13	hance the sharing of domestic and foreign
14	intelligence information among Drug Con-
15	trol Program Agencies related to the pro-
16	duction and trafficking of drugs in the
17	United States and foreign countries; and
18	"(v) activities to prevent the diversion
19	of prescription drugs for illicit use and re-
20	search related to any of these activities.
21	"(2) Inadequacy of transfer.—In the event
22	the authority under this subsection is inadequate to
23	implement the provisions of a plan developed under
24	section 1009, the Director shall submit a request for

1 funding to Congress as soon as the Director becomes 2 aware of the need for additional funding. 3 "(e) Fund Control Notices.— 4 "(1) In general.—The Director may issue to 5 the head of a National Drug Control Program Agency 6 a fund control notice to ensure compliance with the 7 National Drug Control Program Strategy, A fund 8 control notice may direct that all or part of an amount appropriated to the National Drug Control 9 10 Program Agency account be obligated by— "(A) months, fiscal year quarters, or other 11 12 time periods; and 13 "(B) activities, functions, projects, or object 14 classes. 15 "(2) Unauthorized obligation or expendi-Ture prohibited.—An officer or employee of a Na-16 17 tional Drug Control Program Agency shall not make 18 or authorize an expenditure or obligation contrary to 19 a fund control notice issued by the Director. 20 "(3) Disciplinary action for violation.—In 21 the case of a violation of paragraph (2) by an officer 22 or employee of a National Drug Control Program 23 Agency, the head of the agency, upon the request of 24 and in consultation with the Director, may subject 25 the officer or employee to appropriate administrative

- 1 discipline, including, when circumstances warrant,
- 2 suspension from duty without pay or removal from
- 3 *office*.
- 4 "(4) Congressional notice.—Not later than 5
- 5 days after issuance of a fund control notice, the Di-
- 6 rector shall submit a copy of such fund control notice
- 7 to the appropriate congressional committees and make
- 8 such notice publicly available.
- 9 "(5) Restrictions.—The Director shall not
- issue a fund control notice to direct that all or part
- of an amount appropriated to the National Drug
- 12 Control Program Agency account be obligated, modi-
- 13 fied, or altered in any manner contrary, in whole or
- in part, to a specific appropriation or statute.
- 15 "(f) Exclusions.—The authorities described under
- 16 subsections (c), (d), and (e) do not apply to any program
- 17 under subchapter II or III.
- 18 "(g) Foreign Assistance Act Participation.—The
- 19 Director may participate in the drug certification process
- 20 pursuant to section 490 of the Foreign Assistance Act of
- 21 1961 (22 U.S.C. 2291j) and section 706 of the Department
- 22 of State Authorization Act for Fiscal Year 2003 (22 U.S.C.
- 23 229j-l).
- 24 "(h) Certifications of Policy Changes to Direc-
- 25 *TOR.*—

1	"(1) In general.—Subject to paragraph (2), the
2	head of a National Drug Control Program Agency
3	shall, unless exigent circumstances require otherwise,
4	notify the Director in writing regarding any proposed
5	change in policies relating to the activities of that
6	agency under the National Drug Control Program
7	prior to implementation of such change. The Director
8	shall promptly review such proposed change and cer-
9	tify to the head of that agency in writing whether
10	such change is consistent with the National Drug
11	$Control\ Strategy.$
12	"(2) Exception.—If prior notice of a proposed
13	change under paragraph (1) is not practicable—
14	"(A) the head of the National Drug Control
15	Program Agency shall notify the Director of the
16	proposed change as soon as practicable; and
17	"(B) upon such notification, the Director
18	shall review the change and certify to the head
19	of that agency in writing whether the change is
20	consistent with the National Drug Control Strat-
21	egy.
22	"(i) Work in Conjunction With Assistant for
23	National Security Affairs.—The Director shall, in any
24	matter affecting national security interests, work in con-

1	junction with the Assistant to the President for National
2	Security Affairs.
3	"§ 1009. Emerging threats taskforce, plan, media cam-
4	paign
5	"(a) Emerging Threats Task Force.—
6	"(1) Emerging and continuing threats co-
7	ORDINATOR.—The Director shall designate or appoint
8	a United States Emerging and Continuing Threats
9	Coordinator to perform the duties of that position de-
10	scribed in this section and such other duties as may
11	be determined by the Director. The Director shall de-
12	termine whether the coordinator position is a career
13	or noncareer position in the Senior Executive Service.
14	"(2) Establishment and monitoring.—The
15	Emerging and Continuing Threats Coordinator (re-
16	ferred to in this section as the 'Coordinator') shall
17	monitor evolving and emerging drug threats in the
18	United States and shall serve as Chair of an Emerg-
19	ing Threats Task Force (in this section, referred to as
20	the 'task force'). The Director shall appoint other
21	members of the Task force, which shall include rep-
22	resentatives from—
23	"(A) National Drug Control Program Agen-
24	cies or other agencies;
25	"(B) State, local, and Tribal governments;

1	"(C) the Director of the Fusion Center es-
2	tablished in section 1013; and
3	"(D) other entities as determined to be nec-
4	essary by the Director.
5	"(3) Information review and sharing.—
6	"(A) In general.—The task force shall dis-
7	seminate and facilitate the sharing with Federal,
8	State, local, and Tribal officials and other enti-
9	ties as determined by the Director of pertinent
10	information and data relating to the following:
11	"(i) Recent trends in drug supply and
12	demand.
13	"(ii) Fatal and nonfatal overdoses.
14	"(iii) Demand for and availability of
15	evidence-based substance use disorder treat-
16	ment, including the extent of the unmet
17	treatment need, and treatment admission
18	trends.
19	"(iv) Recent trends in drug interdic-
20	tion, supply, and demand from State, local,
21	and Tribal law enforcement agencies.
22	"(v) Other subject matter as deter-
23	mined necessary by the Director.
24	"(B) Contract, agreement, and other
25	AUTHORITY.—The Director may award con-

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

tracts, enter into interagency agreements, manage individual projects, and conduct other operational activities in support of the identification of emerging threats and in support of the development, implementation, and assessment of Emerging Threat Response Plans.

- "(C) Data analysis activities.—In support of the task force, the National Drug Control Fusion Center is authorized to conduct and provide to the task force the results of data analysis activities that the task force requests to aid in their review of recent trends in the data disseminated under subparagraph (A).
- "(4) CRITERIA TO IDENTIFY EMERGING DRUG THREATS.—Not later than 60 days after the date on which a task force first meets, the task force shall develop and recommend to the Director criteria to be used to identify an emerging drug threat or the termination of an emerging drug threat designation based on information gathered by the task force in paragraph (2), statistical data, and other evidence.
- "(5) MEETINGS.—The task force shall meet in person not less frequently than quarterly and at additional meetings if determined to be necessary by and at the call of the Chair to—

1	"(A) identify and discuss evolving and
2	emerging drug trends in the United States using
3	the criteria established in paragraph (3);
4	"(B) formulate the plan described in sub-
5	section (c);
6	"(C) oversee implementation of the plan de-
7	scribed in subsection (c); and
8	"(D) provide such other advice to the Coor-
9	dinator and Director concerning strategy and
10	policies for emerging drug threats and trends as
11	the task force determines to be appropriate.
12	"(b) Designation.—
13	"(1) In general.—The Director, in consultation
14	with the Coordinator, the task force, and the head of
15	each National Drug Control Program Agency, may
16	designate an emerging drug threat in the United
17	States.
18	"(2) Standards for designation.—The Direc-
19	tor, in consultation with the Coordinator, shall pro-
20	mulgate and make publicly available standards by
21	which a designation under paragraph (1) and the ter-
22	mination of such designation may be made. In devel-
23	oping such standards, the Director shall consider the
24	recommendations of the task force and other criteria
25	the Director considers to be appropriate.

"(3) Public statement required.—The Director shall publish a public written statement on the portal of the Office explaining the designation of an emerging drug threat or the termination of such designation and shall notify the appropriate congressional committees of the availability of such statement when a designation or termination of such designation has been made.

"(c) PLAN.—

- "(1) Public availability of Plan.—Not later than 60 days after making a designation under subsection (b), the Director shall publish and make publicly available an Emerging Threat Response Plan and notify the President and the appropriate congressional committees of such plan's availability.
- "(2) TIMING.—Not less frequently than every 90 days after the date on which the plan is published under paragraph (1), the Director shall update the plan and report on implementation of the plan, until the Director issues the public statement required under subsection (b)(3) to terminate the emerging threat designation.
- "(3) Contents of an emerging threat response plan.—The Director shall include in the plan—

1	"(A) a comprehensive strategic assessment
2	of the emerging drug threat, including the cur-
3	rent availability of, demand for, and effectiveness
4	of evidence-based prevention, treatment, and en-
5	forcement programs and efforts to respond to the
6	emerging drug threat;
7	"(B) comprehensive, research-based, long-
8	range, quantifiable goals for addressing the
9	emerging drug threat, including for reducing the
10	supply of the emerging drug threat and for ex-
11	panding the availability and effectiveness of evi-
12	dence-based substance use disorder treatment and
13	prevention programs to reduce the demand for
14	the emerging drug threat;
15	"(C) performance measures pertaining to
16	the plan's goals, including quantifiable and
17	measurable objectives and specific targets;
18	"(D) the level of funding needed to imple-
19	ment the plan, including whether funding is
20	available to be reprogrammed or transferred to
21	support implementation of the plan or whether
22	additional appropriations are necessary to im-
23	plement the plan;
24	"(E) an implementation strategy for the

 $education\ and\ public\ awareness\ campaign\ under$

1	subsection (d), including goals as described
2	under subparagraph (B) and performance meas-
3	ures, objectives, and targets, as described under
4	subparagraph (C); and
5	"(F) any other information necessary to in-
6	form the public of the status, progress, or re-
7	sponse of an emerging drug threat.
8	"(4) Implementation.—
9	"(A) In general.—Not later than 90 days
10	after the date on which a designation is made
11	under subsection (b), the Director, in consulta-
12	tion with the President, the appropriate congres-
13	sional committees, and the head of each National
14	Drug Control Program Agency, shall issue guid-
15	ance on implementation of the plan described in
16	subsection (c) to the National Drug Control Pro-
17	gram Agencies and any other relevant agency de-
18	termined to be necessary by the Director.
19	"(B) Coordinator's responsibilities.—
20	The Coordinator shall—
21	"(i) direct the implementation of the
22	plan among the agencies identified in the
23	plan, State, local, and Tribal governments,
24	and other relevant entities:

1	"(ii) facilitate information-sharing be-
2	tween agencies identified in the plan, State,
3	local, and Tribal governments, and other
4	relevant entities; and
5	"(iii) monitor implementation of the
6	plan by coordinating the development and
7	implementation of collection and reporting
8	systems to support performance measure-
9	ment and adherence to the plan by agencies
10	identified in plan, where appropriate.
11	"(C) Reporting.—Not later than 180 days
12	after designation under subsection (b) and in ac-
13	cordance with paragraph (2)(C), the head of each
14	agency identified in the plan shall submit to the
15	Coordinator a report on implementation of the
16	plan.
17	"(d) Education and Public Awareness Campaign
18	FOR EMERGING DRUG THREATS.—
19	"(1) In General.—Not later than 90 days after
20	a designation under subsection (b), the Director shall
21	establish and implement an evidence-based substance
22	use prevention education and public awareness cam-
23	paign to inform the public about the dangers of any
24	drug designated as an emerging drug threat. Such
25	campaign shall—

1	"(A) educate the public about the dangers of
2	such drug, including patient and family edu-
3	cation about the characteristics and hazards of
4	such drugs and methods to safeguard against
5	such dangers, including the safe disposal of such
6	drugs;
7	"(B) support evidence-based prevention pro-
8	grams targeting audiences' attitudes, percep-
9	tions, and beliefs concerning substance use and
10	intentions to initiate or continue such use;
11	"(C) increase awareness of the negative con-
12	sequences of drug use;
13	"(D) encourage individuals affected by sub-
14	stance use disorders to seek treatment and pro-
15	vide such individuals with information on how
16	to recognize addiction issues, what forms of evi-
17	dence-based treatment options are available, and
18	how to access such treatment; and
19	"(E) combat the stigma of addiction and
20	substance use disorders, including the stigma of
21	treating such disorders with medication-assisted
22	treatment therapies.
23	"(2) Consultation.—For the planning of the
24	campaign under paragraph (1), the Secretary shall
25	consult with—

1	"(A) the head of any appropriate National
2	Drug Control Program Agency to obtain advice
3	on evidence-based scientific information for pol-
4	icy, program development, and evaluation;
5	"(B) experts in evidence-based media cam-
6	paigns, education, evaluation, and communica-
7	tion;
8	"(C) experts on the designated drug;
9	"(D) State, local, and Tribal government of-
10	ficials and relevant agencies;
11	"(E) the public;
12	$``(F)\ appropriate\ congressional\ committees;$
13	and
14	"(G) any other affected person.
15	"(3) Gifts and donations.—
16	"(A) In general.—The Director may ac-
17	cept gifts and donations (in cash or in kind, in-
18	cluding voluntary and uncompensated services or
19	property), which shall be available until ex-
20	pended, for the purpose of supporting the edu-
21	cation and outreach campaign authorized in this
22	section, including the media campaign.
23	"(B) Ethics guidelines.—The Director
24	shall establish written guidelines setting forth the
25	criteria to be used in determining whether a gift

1	or donation should be declined under this section
2	because the acceptance of the gift or donation
3	would—
4	"(i) reflect unfavorably upon the abil-
5	ity of the Director or the Office, or any em-
6	ployee of the Office, to carry out responsibil-
7	ities or official duties under this chapter in
8	a fair and objective manner; or
9	"(ii) compromise the integrity or the
10	appearance of integrity of programs or serv-
11	ices provided under this chapter or of any
12	official involved in those programs or serv-
13	ices.
14	"(C) Annual report required.—Not
15	later than the first Monday in the February of
16	each year, the Director shall submit to the ap-
17	propriate congressional committees an annual
18	report that identifies the sources of any gift or
19	donation accepted by the Office or any con-
20	tractor acting on behalf of the Office, under this
21	subsection, including the value of each gift and
22	donation provided by each source of the gift.
23	"(4) Implementation.—

1	"(A) In general.—For any campaign es-
2	tablished under this subsection, the Director shall
3	ensure the following:
4	"(i) Implementation is evidence-based,
5	meets accepted standards for public aware-
6	ness campaigns, and uses available re-
7	sources in a manner to make the most
8	progress toward achieving the goals identi-
9	fied in the emerging threats plan and para-
10	graph (1).
11	"(ii) Information disseminated through
12	the campaign is accurate.
13	"(iii) The Director approves the strat-
14	egy of the campaign, all material distrib-
15	uted through the campaign, and the use of
16	any Federal funds used for the campaign.
17	"(iv) The campaign is designed using
18	strategies found to be most effective at
19	achieving such goals, which may include—
20	"(I) a media campaign, as de-
21	$scribed\ in\ subparagraph\ (B);$
22	"(II) local, regional, or popu-
23	lation specific messaging;
24	``(III) establishing partnerships
25	and promoting coordination among

1	community stakeholders, including
2	public, nonprofit organizations, and
3	for profit entities;
4	"(IV) providing support, training,
5	and technical assistance to establish
6	and expand school and community
7	$prevention\ programs;$
8	"(V) creating websites to publicize
9	and disseminate information;
10	"(VI) conducting outreach and
11	providing educational resources for
12	parents;
13	"(VII) establishing State or re-
14	gional advisory councils to provide
15	input and recommendations to raise
16	awareness regarding the drug des-
17	ignated as an emerging drug threat;
18	"(VIII) collaborating with law en-
19	forcement; and
20	"(IX) support for school-based
21	public health education classes to im-
22	prove teen knowledge about the effects
23	of such designated drug.

1	"(B) Media campaign.—Any campaign
2	implemented under this subsection may include
3	a media component, which—
4	"(i) shall be designed to prevent the use
5	of the drug designated as an emerging drug
6	threat and to achieve the goals of paragraph
7	(1);
8	"(ii) shall be carried out through com-
9	petitively awarded contracts to entities pro-
10	viding for the professional production and
11	design of such campaign; and
12	"(iii) may include the use of television,
13	radio, Internet, social media, and other
14	commercial marketing venues and may be
15	targeted to specific age groups based on
16	peer-reviewed social research.
17	"(C) REQUIRED NOTICE FOR COMMUNICA-
18	TION FROM THE OFFICE.—Any communication,
19	including an advertisement, paid for or other-
20	wise disseminated by the Office directly or
21	through a contract awarded by the Office shall
22	include a prominent notice informing the audi-
23	ence that the communication was a paid for by
24	of the Office.
25	"(5) Evaluation.—

1	"(A) Performance evaluation.—The Di-
2	rector shall include an evaluation of the cam-
3	paign in the annual assessment under section
4	1006, which shall include the following:
5	"(i) A performance evaluation of the
6	campaign, including progress toward meet-
7	ing the goals, objectives, measures, and tar-
8	gets identified in the emerging threats plan.
9	"(ii) A description of all policies and
10	practices to eliminate the potential for
11	waste, fraud, abuse, and to ensure Federal
12	funds are used responsibly.
13	"(iii) A list of all contracts or other
14	agreements entered into to implement the
15	campaign.
16	"(iv) The results of any financial audit
17	of the campaign.
18	"(v) A description of any evidence used
19	to develop the campaign.
20	"(B) Independent evaluation.—Not
21	later than 180 days after establishing a cam-
22	paign under paragraph (1) and not less than
23	frequently than every two years thereafter, the
24	Director shall—

1	"(i) designate an independent entity to
2	evaluate the effectiveness of the campaign
3	with meeting the goals established in the
4	emerging threat plan and paragraph (1);
5	and
6	"(ii) submit the results of the inde-
7	pendent evaluation to the appropriate con-
8	$gressional\ committees.$
9	"(6) Funding prohibitions.—None of the
10	amounts made available under this subsection may be
11	obligated for any of the following:
12	"(A) To supplant current anti-drug commu-
13	nity-based coalitions.
14	"(B) To supplant pro bono public service
15	time donated by national and local broadcasting
16	network for other public services campaigns.
17	"(C) For partisan political purposes, or ex-
18	press advocacy in support of or to defeat any
19	clearly identified candidate, clearly identified
20	ballot initiative, or clearly identified legislative
21	or regulatory proposal.
22	"(D) For any advocacy in support of any
23	particular company, industry association, or ad-
24	vocacy group or the explicit policy positions held
25	by such groups.

1	"(E) To direct any individuals to a specific
2	type of substance use disorder treatment, treat-
3	ment facility, medical provider, or form of medi-
4	cation assisted treatment.
5	"(F) To fund any advertising that features
6	any elected officials, persons seeking elected of-
7	fice, cabinet level officials, or other Federal offi-
8	cials employed pursuant to section 213 of Sched-
9	ule C of title 5, Code of Federal Regulations.
10	"(e) Authorization of Appropriations.—There is
11	authorized to be appropriated to the Office to carry out this
12	section, \$25,000,000 for each of fiscal years 2019 through
13	2023.
13 14	2023. "§ 1010. National and international coordination
14	"§ 1010. National and international coordination
14 15	"§ 1010. National and international coordination "(a) DISSEMINATION OF RESEARCH AND INFORMATION
14 15 16 17	"\$ 1010. National and international coordination "(a) DISSEMINATION OF RESEARCH AND INFORMATION TO STATES.—The Director shall ensure that drug control
14 15 16 17	"\$ 1010. National and international coordination "(a) DISSEMINATION OF RESEARCH AND INFORMATION TO STATES.—The Director shall ensure that drug control research and information is effectively disseminated by Na-
14 15 16 17	"\$ 1010. National and international coordination "(a) DISSEMINATION OF RESEARCH AND INFORMATION TO STATES.—The Director shall ensure that drug control research and information is effectively disseminated by Na- tional Drug Control Program Agencies to State and local
114 115 116 117 118	"\$1010. National and international coordination "(a) DISSEMINATION OF RESEARCH AND INFORMATION TO STATES.—The Director shall ensure that drug control research and information is effectively disseminated by Na- tional Drug Control Program Agencies to State and local governments and nongovernmental entities involved in de-
14 15 16 17 18 19 20	"\$ 1010. National and international coordination "(a) DISSEMINATION OF RESEARCH AND INFORMATION TO STATES.—The Director shall ensure that drug control research and information is effectively disseminated by National Drug Control Program Agencies to State and local governments and nongovernmental entities involved in demand reduction by—
14 15 16 17 18 19 20 21	"\$1010. National and international coordination "(a) DISSEMINATION OF RESEARCH AND INFORMATION TO STATES.—The Director shall ensure that drug control research and information is effectively disseminated by National Drug Control Program Agencies to State and local governments and nongovernmental entities involved in demand reduction by— "(1) encouraging formal consultation between
14 15 16 17 18 19 20 21	"\$1010. National and international coordination "(a) DISSEMINATION OF RESEARCH AND INFORMATION TO STATES.—The Director shall ensure that drug control research and information is effectively disseminated by National Drug Control Program Agencies to State and local governments and nongovernmental entities involved in demand reduction by— "(1) encouraging formal consultation between any such agency that conducts or sponsors research,

1	"(2) encouraging such agencies (as appropriate)
2	to develop and implement dissemination plans that
3	specifically target State and local governments and
4	nongovernmental entities involved in demand reduc-
5	tion; and
6	"(3) supporting the substance abuse information
7	clearinghouse administered by the Administrator of
8	the Substance Abuse and Mental Health Services Ad-
9	$ministration \ and \ established \ in \ section \ 501(d)(16) \ of$
10	the Public Health Service Act by—
11	"(A) encouraging all National Drug Control
12	Program Agencies to provide all appropriate and
13	relevant information; and
14	"(B) supporting the dissemination of infor-
15	mation to all interested entities.
16	"(b) STANDARDS.—
17	"(1) Development.—The Director shall coordi-
18	nate the development of evidence-based standards de-
19	veloped by National Drug Control Program Agencies
20	and other relevant agencies and non-Federal entities
21	to State, local, and Tribal governments and non-
22	governmental entities related to drug control policies,
23	practices, and procedures, such as the investigation of
24	drug-related deaths, by—

1	"(A) encouraging appropriate agencies and
2	State, local, and Tribal governments to develop
3	data standards for drug control practices and
4	procedures and related statistical data;
5	"(B) encouraging information sharing be-
6	tween appropriate agencies and State, local, and
7	Tribal governments of relevant drug control in-
8	formation and data;
9	"(C) establishing a working group of agen-
10	cies, State, local, and Tribal governments, and
11	other relevant stakeholders to discuss and develop
12	such standards; and
13	"(D) facilitating collaboration among agen-
14	cies, non-Federal entities, States, local, and Trib-
15	al governments, and nongovernmental agencies.
16	"(2) Implementation.—The Director shall pro-
17	mote the implementation of the standards described in
18	paragraph (1) by—
19	"(A) encouraging adoption by providing the
20	standards to State and local governments
21	through the internet, annual publications or
22	periodicals, and other widely-disseminated
23	means; and

1	"(B) facilitating the use and dissemination
2	of such standards among State and local govern-
3	ments by—
4	"(i) providing technical assistance to
5	State, local, and Tribal governments seeking
6	to adopt or implement such standards; and
7	"(ii) coordinating seminars and train-
8	ing sessions for State, local, and Tribal gov-
9	ernments seeking to adopt or implement
10	such standards.
11	"(c) Private Sector.—
12	"(1) In general.—The Director or the head of
13	a National Drug Control Program (as designated by
14	the Director) shall coordinate with the private sector
15	to promote private research and development of medi-
16	cations to treat or prevent addiction, including re-
17	search and development for non-addictive pain man-
18	agement medication, abuse deterrent formulations,
19	medication-assisted treatment, and other addiction re-
20	search determined to be necessary by the Director
21	by—
22	"(A) encouraging the sharing of informa-
23	tion regarding evidence-based treatment addic-
24	tion findings and related data between agencies
25	and the private sector, as appropriate;

1	"(B) encouraging collaboration between ap-
2	propriate agencies and the private sector; and
3	"(C) providing private sector entities with
4	relevant statistical data and information to en-
5	hance research as permissible.
6	"(2) Working group.—The Director may estab-
7	lish a working group of National Drug Control Pro-
8	gram Agencies, State, local, and Tribal governments,
9	and the private sector stakeholders to discuss and dis-
10	seminate best practices, research and development,
11	and other related issues, as appropriate.
12	"(d) Model Acts Program.—
13	"(1) In general.—The Director shall provide
14	for or shall enter into an agreement with a nonprofit
15	organization to—
16	"(A) advise States on establishing laws and
17	policies to address illicit drug use issues; and
18	"(B) revise such model State drug laws and
19	draft supplementary model State laws to take
20	into consideration changes in illicit drug use
21	issues in the State involved.
22	"(2) Authorization of appropriations.—
23	There is authorized to be appropriated to carry out
24	this subsection \$1,250,000 for each of fiscal years
25	2019 through 2023.

1	"(e) Drug Court Training and Technical Assist-
2	ANCE PROGRAM.—
3	"(1) Grants authorized.—The Director may
4	make a grant to a nonprofit organization for the pur-
5	pose of providing training and technical assistance to
6	drug courts.
7	"(2) Authorization of Appropriations.—
8	There is authorized to be appropriated to carry out
9	this subsection \$2,000,000 for each of fiscal years
10	2019 through 2023.
11	"(f) International Coordination.—The Director
12	shall facilitate international drug control coordination ef-
13	forts.
14	"(g) State, Local, and Tribal Affairs Coordi-
15	NATOR.—The Director shall designate or appoint a United
16	States State, Local, and Tribal Affairs Coordinator to per-
17	form the duties of the Office outlined in this section and
18	section 1005 and such other duties as may be determined
19	by the Director with respect to coordination of drug control
20	efforts between agencies and State, local, and Tribal govern-
21	ments. The Director shall determine whether the coordinator
22	position is a career or noncareer position in the Senior Ex-
23	ecutive Service.
24	"§ 1011. Interdiction
25	"(a) United States Interdiction Coordinator.—

1	"(1) In general.—The Director shall designate
2	or appoint a United States Interdiction Coordinator
3	to perform the duties of that position described in
4	paragraph (2) and such other duties as may be deter-
5	mined by the Director with respect to coordination of
6	efforts to interdict illicit drugs from entering the
7	United States.
8	"(2) Responsibilities.—The United States
9	Interdiction Coordinator shall be responsible to the
10	Director for—
11	"(A) coordinating the interdiction activities
12	of the National Drug Control Program Agencies
13	to ensure consistency with the National Drug
14	$Control\ Strategy;$
15	"(B) on behalf of the Director, developing
16	and issuing, on or before March 1 of each year
17	and in accordance with paragraph (4), a Na-
18	tional Interdiction Command and Control Plan
19	to ensure the coordination and consistency de-
20	$scribed\ in\ subparagraph\ (A);$
21	"(C) assessing the sufficiency of assets com-
22	mitted to illicit drug interdiction by the relevant
23	National Drug Control Program Agencies; and
24	"(D) advising the Director on the efforts of
25	each National Drug Control Program Agency to

1	implement the National Interdiction Command
2	and Control Plan.
3	"(3) Staff.—The Director shall assign such per-
4	manent staff of the Office as he considers appropriate
5	to assist the United States Interdiction Coordinator
6	to carry out the responsibilities described in para-
7	graph (2), and may request that appropriate Na-
8	tional Drug Control Program Agencies detail or as-
9	sign staff to assist in carrying out such activities.
10	"(4) National interdiction command and
11	CONTROL PLAN.—
12	"(A) Purposes.—The National Interdic-
13	tion Command and Control Plan—
14	"(i) shall set forth the Government's
15	strategy for drug interdiction;
16	"(ii) shall state the specific roles and
17	responsibilities of the relevant National
18	Drug Control Program Agencies for imple-
19	$menting\ that\ strategy;$
20	"(iii) shall identify the specific re-
21	sources required to enable the relevant Na-
22	tional Drug Control Program Agencies to
23	implement that strategy; and

1	"(iv) may include recommendations
2	about changes to existing agency authorities
3	or laws governing interagency relationships.
4	"(B) Consultation with other agen-
5	cies.—Before the submission of the National
6	Drug Control Strategy or annual supplement re-
7	quired under section 1005(d), as applicable, the
8	United States Interdiction Coordinator shall
9	issue the National Interdiction Command and
10	Control Plan, in consultation with the other
11	members of the Interdiction Committee described
12	in subsection (c).
13	"(C) Report to congress.—On or before
14	March 1 of each year, the Director, through the
15	United States Interdiction Coordinator, shall
16	provide to the appropriate congressional commit-
17	tees, to the Committee on Armed Services and the
18	Committee on Homeland Security of the House
19	of Representatives, and to the Committee on
20	Homeland Security and Governmental Affairs
21	and the Committee on Armed Services of the
22	Senate, a report that includes—
23	"(i) a copy of that year's National
24	Interdiction Command and Control Plan;

1	"(ii) information for the previous 10
2	years regarding the number and type of sei-
3	zures of drugs by each National Drug Con-
4	trol Program Agency conducting drug inter-
5	diction activities and statistical informa-
6	tion on the geographic areas of such sei-
7	zures; and
8	"(iii) information for the previous 10
9	years regarding the number of air and mar-
10	itime patrol hours undertaken by each Na-
11	tional Drug Control Program Agency con-
12	ducting drug interdiction activities and sta-
13	tistical information on the geographic areas
14	in which such patrol hours took place.
15	"(D) Classified annex.—The report sub-
16	mitted pursuant to subparagraph (C) may in-
17	clude a classified annex.
18	"(b) Interdiction Committee.—
19	"(1) In General.—The Interdiction Committee
20	shall meet to—
21	"(A) discuss and resolve issues related to the
22	coordination, oversight, and integration of inter-
23	national, border, and domestic drug interdiction
24	efforts in support of the National Drug Control
25	Strategy;

- 1 "(B) review the annual National Interdic-2 tion Command and Control Plan, and provide 3 advice to the Director and the United States 4 Interdiction Coordinator concerning that plan; 5 and
 - "(C) provide such other advice to the Director concerning drug interdiction strategy and policies as the committee determines is appropriate.
 - "(2) Chair.—The Director shall designate one of the members of the Interdiction Committee to serve as chair.
 - "(3) MEETINGS.—The members of the Interdiction Committee shall meet, in person and not through any delegate or representative, at least once per calendar year, before March 1. At the call of the Director or the chair, the Interdiction Committee may hold additional meetings, which shall be attended by the members in person, or through such delegates or representatives as the members may choose.
 - "(4) Report.—Not later than September 30 of each year, the chair of the Interdiction Committee shall submit to the Director and to the appropriate congressional committees a report describing the results of the meetings and any significant findings of

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1	the committee during the previous 12 months. Such
2	report may include a classified annex.
3	"§ 1012. Treatment coordinator
4	"(a) United States Treatment Coordinator.—
5	"(1) In general.—The Director shall designate
6	or appoint a United States Treatment Coordinator to
7	perform the responsibilities of that position described
8	in paragraph (2) and such other duties as may be de-
9	termined by the Director with respect to coordination
10	of efforts to expand the availability of substance use
11	disorder treatment with the goal of eliminating the
12	unmet treatment need.
13	"(2) Responsibilities.—The United States
14	Treatment Coordinator shall be responsible to the Di-
15	rector for—
16	"(A) coordinating the activities of the Na-
17	tional Drug Control Program Agencies under-
18	taken to expand the availability of evidence-
19	based substance use disorder treatment to ensure
20	consistency with the National Drug Control
21	Strategy;
22	"(B) on behalf of the Director, developing
23	and issuing, on or before March 1 of each year
24	and in accordance with paragraph (4), a Na-
25	tional Treatment Plan to ensure the coording-

1	tion and consistency described in subparagraph
2	(A);
3	"(C) assessing the sufficiency of Federal re-
4	sources directed to substance use disorder treat-
5	ment by the relevant National Drug Control Pro-
6	gram Agencies;
7	"(D) encouraging the adoption by all sub-
8	stance use disorder treatment providers of evi-
9	dence-based standards to guide all aspects of
10	treatment provided; and
11	"(E) advising the Director on the efforts of
12	each National Drug Control Program Agency to
13	implement the National Treatment Plan.
14	"(3) Staff.—The Director shall assign such per-
15	manent staff of the Office of the United States Treat-
16	ment Coordinator as the Director determines to be ap-
17	propriate to assist the United States Treatment Coor-
18	dinator to carry out the responsibilities described in
19	paragraph (2), and may request that appropriate Na-
20	tional Drug Control Program Agencies detail or as-
21	sign staff to assist in carrying out such responsibil-
22	ities.
23	"(4) National treatment plan.—
24	"(A) Purposes.—The National Treatment
25	Plan—

1	"(i) shall identify the unmet need for
2	treatment for evidence-based substance use
3	disorders including opioid use disorders,
4	and set forth the Government's strategy for
5	closing the gap between available and need-
6	ed treatment through all sources;
7	"(ii) shall describe the specific roles
8	and responsibilities of the relevant National
9	Drug Control Program Agencies for imple-
10	menting that strategy;
11	"(iii) shall identify the specific re-
12	sources required to enable the relevant Na-
13	tional Drug Control Program Agencies to
14	implement that strategy;
15	"(iv) shall identify the resources, in-
16	cluding private sources, required to elimi-
17	nate the unmet need for evidence-based sub-
18	stance use disorder treatment; and
19	"(v) may include recommendations
20	about changes to existing agency authorities
21	or laws governing interagency relationships.
22	"(B) Consultation with other agen-
23	cies.—Before the submission of the National
24	Treatment Strategy or annual supplement re-
25	guired under section 1005(d), as applicable, the

1	United States Treatment Coordinator shall issue
2	the National Treatment Plan, in consultation
3	with the other members of the Interdiction Com-
4	mittee described in subsection (b).
5	"(C) Report to congress.—On or before
6	March 1 of each year, the Director, through the
7	United States Treatment Coordinator, shall pro-
8	vide to the appropriate congressional committees
9	a report that includes a copy of that year's Na-
10	tional Treatment Plan;
11	"(b) Treatment Committee.—
12	"(1) In General.—The Treatment Committee
13	shall meet to—
14	"(A) review and discuss the adequacy of
15	evidence-based substance use disorder treatment
16	as well as the unmet need for treatment;
17	"(B) review and discuss the status of the
18	implementation of the National Treatment Plan;
19	and
20	"(C) provide such other advice to the Direc-
21	tor concerning substance use disorder treatment
22	initiatives as the committee determines is appro-
23	priate.

1 "(2) CHAIR.—The Director shall designate one of 2 the members of the Treatment Committee to serve as 3 chair.

> "(3) MEETINGS.—The members of the Treatment Committee shall meet, in person and not through any delegate or representative, at least once per calendar year, before March 1. At the call of the Director or the chair, the Treatment Committee may hold additional meetings, which shall be attended by the members in person, or through such delegates or representatives as the members may choose.

> "(4) Report.—Not later than September 30 of each year, the chair of the Treatment Committee shall submit to the Director and to the appropriate congressional committees a report describing the results of the meetings and any significant findings of the committee during the previous 12 months. Such report may include a classified annex.

19 "§ 1013. Critical information coordination

20 "(a) National Drug Control Fusion Center.—

"(1) ESTABLISHMENT.—The Director shall, in consultation with the head of each National Drug Control Program Agency, designate an agency to establish a National Drug Control Fusion Center (referred to in this section as the 'Center'). The Center

5

6

7

8

9

10

11

12

13

14

15

16

17

18

21

22

23

24

1 shall operate under the authority of the Director and 2 shall work with the National Drug Control Program 3 Agencies to collect, compile, analyze, and facilitate the 4 sharing of data on the use of illicit drugs, treatment 5 for substance use disorder, and interdiction of illicit 6 drugs. The Center shall be considered a 'statistical 7 agency or unit', as that term is defined in section 502 8 of the Confidential Information Protection and Sta-9 tistical Efficiency Act of 2002 (44 U.S.C. 3501 note) 10 and shall have the necessary independence to ensure 11 any data or information acquired by an agency 12 under a pledge of confidentiality and for exclusively 13 statistical purposes is used exclusively for statistical 14 purposes.

- "(2) Center director.—There shall be at the head of the Center a Center Director who shall be appointed by the Director from among individuals qualified and distinguished in data governance and statistical analysis.
- "(3) Data compilation.—The Director, acting through the Center Director, shall do the following:
- 22 "(A) Coordinate data collection activities 23 among the National Drug Control Program 24 Agencies.

15

16

17

18

19

20

1	"(B) Collect information not otherwise col-
2	lected by National Drug Control Program Agen-
3	cies as necessary to inform the National Drug
4	$Control\ Strategy.$
5	"(C) Compile and analyze any data re-
6	quired to be collected under this chapter.
7	"(D) Disseminate technology, as appro-
8	priate, to States and local jurisdictions to enable
9	or improve the collection of data on drug use, in-
10	cluding the recordation of the occurrence of fatal
11	and non-fatal drug overdoses.
12	"(E) Compile information collected by Na-
13	tional Drug Control Program Agencies on grants
14	issued through any National Drug Control Pro-
15	gram, including for any grant the following:
16	"(i) The recipient.
17	"(ii) The amount.
18	"(iii) The intended purpose.
19	"(iv) Any evidence of the efficacy of the
20	outcomes achieved by the program funded
21	through the grant.
22	"(v) Any assessments of how the grant
23	met its intended purpose.
24	"(4) Toxicology screening.—

1	"(A) Establishment.—The Center Direc-
2	tor may establish a toxicology screening program
3	that engages in—
4	"(i) secondary analysis of urine sam-
5	ples that would otherwise be discarded by—
6	"(I) hospitals and drug treatment
7	programs;
8	"(II) correctional facilities, book-
9	ing sites, probation programs, drug
10	courts, and related facilities; and
11	"(III) coroners and medical exam-
12	iners; and
13	"(ii) analysis of other physical sam-
14	ples, as determined by the Center Director
15	to be valuable for understanding the preva-
16	lence of any illicit drug.
17	"(B) DE-IDENTIFICATION OF INFORMA-
18	TION.—The Center Director shall ensure that no
19	samples have any personally identifiable infor-
20	mation prior to collection.
21	"(C) Limitation on use.—No data ob-
22	tained from analysis conducted under this para-
23	graph may be used as evidence in any pro-
24	ceeding.

1 "(D) STATE PROGRAM.—The Center Direc-2 tor may establish a program that enables States 3 and local jurisdictions to submit up to 20 urine 4 samples per year for toxicology analysis for the 5 purposes of identifying substances present in in-6 dividuals who have suffered fatal drug overdoses.

- "(5) AUTHORITY TO CONTRACT.—The Director may award contracts, enter into interagency agreements, manage individual projects, and conduct other operational activities under this subsection.
- 11 "(b) Critical Drug Control Information and 12 Evidence Plan.—

"(1) In General.—Not later than the first Monday in February of each year, the Director shall submit to Congress a systematic plan for increasing data collection to enable real-time surveillance of drug control threats, developing analysis and monitoring capabilities, and identifying and addressing policy questions relevant to the National Drug Control Policy, Strategy, and Program. Such plan shall be made available on the public online portal of the Office, shall cover at least a 4-year period beginning with the first fiscal year following the fiscal year in which the plan is submitted and published, and contain the following:

7

8

9

10

13

14

15

16

17

18

19

20

21

22

23

24

1	"(A) A list of policy-relevant questions for
2	which the Director and each National Drug Con-
3	trol Program Agency intends to develop evidence
4	to support the National Drug Control Program
5	and Strategy.
6	"(B) A list of data the Director and each
7	National Drug Control Program Agency intends
8	to collect, use, or acquire to facilitate the use of
9	evidence in drug control policymaking and mon-
10	itoring.
11	"(C) A list of methods and analytical ap-
12	proaches that may be used to develop evidence to
13	support the National Drug Control Program and
14	Strategy and related policy.
15	"(D) A list of any challenges to developing
16	evidence to support policymaking, including any
17	barriers to accessing, collecting, or using relevant
18	data.
19	"(E) A description of the steps the Director
20	and the head of each National Drug Control Pro-
21	gram Agency will take to effectuate the plan.
22	"(F) Any other relevant information as de-
23	termined by the Director.

1	"(2) Consultation.—In developing the plan re-
2	quired under paragraph (1), the Director shall con-
3	sult with the following:
4	"(A) The public.
5	"(B) Any evaluation or analysis units and
6	personnel of the Office.
7	"(C) Office officials responsible for imple-
8	menting privacy policy.
9	"(D) Office officials responsible for data
10	governance.
11	"(E) The appropriate congressional com-
12	mittees.
13	"(F) Any other individual or entity as de-
14	termined by the Director.
15	"(c) Evidence-based Policy.—
16	"(1) Harm reduction programs.—When de-
17	veloping the national drug control policy, any policy
18	of the Director, including policies relating to syringe
19	exchange programs for intravenous drug users, shall
20	be based on the best available medical and scientific
21	evidence regarding the effectiveness of such policy in
22	promoting individual health, preventing the spread of
23	infectious disease and the impact of such policy on
24	drug addiction and use. In making any policy relat-
25	ing to harm reduction programs, the Director shall

- consult with the National Institutes of Health and the
 National Academy of Sciences.
- 3 "(2) Fund restriction for the legalization
 4 OF Controlled Substances.—The Director shall
 5 ensure that no Federal funds appropriated to the Of6 fice shall be expended for any study or contract relat7 ing to the legalization (for a medical use or any other
 8 use) for which a listing in schedule I is in effect
 9 under section 202 of the Controlled Substances Act
 10 (21 U.S.C. 812).

"(d) Drug Control Data Dashboard.—

- "(1) ESTABLISHMENT.—The Director, in consultation with the Center Director, shall establish and maintain a data dashboard on the online portal of the Office to be known as the 'Drug Control Data Dashboard'. The Director shall ensure the user interface of the dashboard is constructed with modern design standards. To the extent practicable, the data made available on the dashboard shall be publicly available in a machine-readable format and searchable by year, agency, drug, and location.
- "(2) DATA.—The data included in the Drug Control Data Dashboard shall be updated not less frequently than quarterly and shall include, at a minimum, the following:

1	"(A) For each substance identified under
2	section $1005(c)(1)(A)(i)$ —
3	"(i) the total amount seized and dis-
4	rupted in the calendar year and each of the
5	previous 3 calendar years;
6	"(ii) the known and estimated flows
7	into the United States from all sources in
8	the calendar year and each of the previous
9	3 calendar years;
10	"(iii) the total amount of known flows
11	that could not be interdicted or disrupted in
12	the calendar year and each of the previous
13	3 calendar years;
14	"(iv) the known and estimated levels of
15	domestic production in the calendar year
16	and each of the previous three calendar
17	years, including the levels of domestic pro-
18	duction if the drug is a prescription drug,
19	as determined under the Federal Food,
20	Drug, and Cosmetic Act, for which a listing
21	is in effect under section 202 of the Con-
22	trolled Substances Act (21 U.S.C. 812); and
23	"(v) the average street price for the cal-
24	endar year and the highest known street
25	price during the preceding 10-year period.

1	"(B) For the calendar year and each of the
2	previous three years data sufficient to show,
3	disaggregated by State and, to the extent feasible,
4	by region within a State, county, or city, the fol-
5	lowing:
6	"(i) The number of fatal and non-fatal
7	overdoses caused by each drug identified
8	$under\ subparagraph\ (A)(i).$
9	"(ii) The prevalence of substance use
10	disorders.
11	"(iii) The number of individuals who
12	have received substance use disorder treat-
13	ment, including medication assisted treat-
14	ment, for a substance use disorder, includ-
15	ing treatment provided through publicly-fi-
16	nanced health care programs.
17	"(iv) The extent of the unmet need for
18	substance use disorder treatment, including
19	the unmet need for medication-assisted
20	treatment.
21	"(C) Data sufficient to show the extent of
22	prescription drug diversion, trafficking, and
23	misuse in the calendar year and each of the pre-
24	vious 3 calendar years.

1	"(D) Any quantifiable measures the Direc-
2	tor determines to be appropriate to detail
3	progress toward the achievement of the goals of
4	the National Drug Control Strategy.
5	"(e) Access to Information.—
6	"(1) In general.—Upon the request of the Di-
7	rector, the head of any National Drug Control Pro-
8	gram Agency shall cooperate with and provide to the
9	Director any statistics, studies, reports, and other in-
10	formation prepared or collected by the agency con-
11	cerning the responsibilities of the agency under the
12	National Drug Control Strategy that relate to—
13	"(A) drug control; or
14	"(B) the manner in which amounts made
15	available to that agency for drug control are
16	being used by that agency.
17	"(2) Protection of intelligence informa-
18	TION.—
19	"(A) In General.—The authorities con-
20	ferred on the Office and the Director by this
21	chapter shall be exercised in a manner consistent
22	with provisions of the National Security Act of
23	1947 (50 U.S.C. 401 et seq.). The Director of Na-
24	tional Intelligence shall prescribe such regula-
25	tions as may be necessary to protect information

provided pursuant to this chapter regarding intelligence sources and methods.

- "(B) DUTIES OF DIRECTOR.—The Director of National Intelligence and the Director of the Central Intelligence Agency shall, to the maximum extent practicable in accordance with subparagraph (A), render full assistance and support to the Office and the Director.
- "(3) REQUIRED REPORTS FROM NATIONAL DRUG CONTROL AGENCIES.—The head of each National Drug Control Program Agency shall submit to the Director such information and reports as requested from such National Drug Control Program Agency by the Director, which shall include from the appropriate National Drug Control Program Agencies:

"(A) Not later than July 1 of each year, the head of a designated National Drug Control Program Agency shall submit to the Director and the appropriate congressional committees an assessment of the quantity of illegal drug cultivation and manufacturing in the United States on lands owned or under the jurisdiction of their respective agencies that was seized or eradicated by their personnel during the preceding calendar year.

1	"(B) Not later than July 1 of each year, the
2	head of a designated National Drug Control Pro-
3	gram Agency shall submit to the Director and
4	the appropriate congressional committees infor-
5	mation for the preceding year regarding—
6	"(i) the number and type of seizures of
7	drugs by each component of the agency seiz-
8	ing drugs, as well as statistical information
9	on the geographic areas of such seizures;
10	and
11	"(ii) the number of air and maritime
12	patrol hours primarily dedicated to drug
13	supply reduction missions undertaken by
14	each component of the agency.
15	"(C) Not later than July 1 of each year, the
16	head of a designated National Drug Control Pro-
17	gram Agency shall submit to the Director and
18	the appropriate congressional committees infor-
19	mation for the preceding year regarding the
20	number of air and maritime patrol hours pri-
21	marily dedicated to drug supply reduction mis-
22	sions undertaken by each component of the agen-
23	cy.
24	"(D) Not later than July 1 of each year, the
25	head of a designated National Drug Control Pro-

1	gram Agency shall submit to the Director and
2	the appropriate congressional committees infor-
3	mation for the preceding year regarding the
4	number and type of—
5	"(i) arrests for drug violations;
6	"(ii) prosecutions for drug violations
7	by United States Attorneys; and
8	"(iii) seizures of drugs by each compo-
9	nent of the Department of Justice seizing
10	drugs, as well as statistical information on
11	the geographic areas of such seizures.
12	"(f) Data Exchange Standards for Improved
13	Interoperability.—
14	"(1) Interagency and intergovernmental
15	DESIGNATION AND USE OF DATA EXCHANGE STAND-
16	ARDS WORKING GROUP.—The Director shall establish
17	a working group of National Drug Control Program
18	Agencies, State, local and Tribal government health
19	and law enforcement agencies, and data governance
20	experts to develop consensus data exchange standards
21	for necessary categories of information that allow ef-
22	fective electronic exchange of information between
23	States, between State agencies, between States and
24	National Drug Control Program Agencies, and any
25	other drug control relevant data exchange.

1	"(2) Data exchange standards must be non-
2	PROPRIETARY AND INTEROPERABLE.—The data ex-
3	change standards designated under paragraph (1)
4	shall, to the extent practicable, be nonproprietary and
5	interoperable.
6	"(3) Other requirements.—In designating
7	data exchange standards under this subsection, the
8	working group shall, to the extent practicable, incor-
9	porate—
10	"(A) interoperable standards developed and
11	maintained by an international voluntary con-
12	sensus standards body, as defined by the Office
13	$of\ Management\ and\ Budget;$
14	"(B) interoperable standards developed and
15	maintained by intergovernmental partnerships;
16	and
17	"(C) interoperable standards developed and
18	maintained by Federal entities with authority
19	over contracting and financial assistance.
20	"(4) Data exchange standards for federal
21	REPORTING.—
22	"(A) Designation.—The Director may, in
23	consultation with the working group established
24	under this section, National Drug Control Pro-
25	gram Agencies, and State, local, and Tribal gov-

1	ernments, designate data exchange standards to
2	govern Federal reporting and exchange require-
3	ments for National Drug Control Programs, as
4	appropriate.
5	"(B) Requirements.—The data exchange
6	reporting standards required by subparagraph
7	(A) shall, to the extent practicable—
8	"(i) incorporate a widely accepted,
9	nonproprietary, searchable, machine-read-
10	$able\ format;$
11	"(ii) be consistent with and implement
12	$applicable\ accounting\ principles;$
13	"(iii) be implemented in a manner
14	that is cost-effective and improves program
15	efficiency and effectiveness; and
16	"(iv) be capable of being continually
17	upgraded as necessary.
18	"(C) Incorporation of nonproprietary
19	STANDARDS.—In designating data exchange
20	standards under this paragraph, the Director
21	shall, to the extent practicable, incorporate exist-
22	ing nonproprietary standards.
23	"(D) Rule of construction.—Nothing in
24	this paragraph shall be construed to require a
25	change to existing data exchange standards for

1	Federal reporting about a program referred to in
2	this section, if the head of the agency responsible
3	for administering the program finds the stand-
4	ards to be effective and efficient.
5	"(5) Termination.—The working group estab-
6	lished under paragraph (1) shall terminate not ear-
7	lier than 60 days after the public notification of ter-
8	mination by the Director.
9	"(g) Annual Data Collection and Dissemination
10	Requirements.—
11	"(1) In General.—The Director shall collect
12	and disseminate, as appropriate, such information as
13	the Director determines is appropriate, but not less
14	than the information described in this subsection. To
15	the extent practicable, the data shall be publicly
16	available in a machine-readable format on the Drug
17	Control Data Dashboard, be searchable by year, agen-
18	cy, drug, and location, and cover not less than the
19	previous 10-year period.
20	"(2) Preparation and dissemination of in-
21	FORMATION.—The Director shall prepare and dis-
22	seminate the following:
23	"(A) An assessment of current illicit drug
24	use (including inhalants and steroids) and avail-

1	ability, impact of illicit drug use, and treatment
2	availability, which assessment shall include—
3	"(i) estimates of drug prevalence and
4	frequency of use as measured by national,
5	State, and local surveys of illicit drug use
6	and by other special studies of non-
7	dependent and dependent illicit drug use;
8	"(ii) illicit drug use in the workplace
9	and the productivity lost by such use; and
10	"(iii) illicit drug use by arrestees, pro-
11	bationers, and parolees.
12	"(B) An assessment of the reduction of il-
13	licit drug availability, for each drug identified
14	under section $1005(c)(1)(A)(i)$, as measured by—
15	"(i) the quantities of such drug avail-
16	able for consumption in the United States;
17	"(ii) the amount of such drug entering
18	the United States;
19	"(iii) the number of illicit drug manu-
20	facturing laboratories seized and destroyed
21	of each relevant drug and the number of
22	hectares cultivated and destroyed domesti-
23	cally and in other countries of each relevant
24	drug;

1	"(iv) the number of metric tons of such
2	drug seized; and
3	"(v) changes in the price and purity of
4	such drug.
5	"(C) An assessment of the reduction of the
6	consequences of illicit drug use and availability,
7	which shall include—
8	"(i) the cost of treating substance use
9	disorder in the United States, such as the
10	quantity of illicit drug-related services pro-
11	vided;
12	"(ii) the annual national health care
13	cost of illicit drug use; and
14	"(iii) the extent of illicit drug-related
15	crime and criminal activity.
16	"(D) A determination of the status of drug
17	treatment in the United States, by assessing—
18	"(i) public and private treatment utili-
19	zation; and
20	"(ii) the number of illicit drug users
21	the Director estimates meet diagnostic cri-
22	teria for treatment.
23	"(E) A summary of the efforts made to co-
24	ordinate with private sector entities to conduct

1	private research and development of medications
2	to treat addiction by—
3	"(i) screening chemicals for potential
4	therapeutic value;
5	"(ii) developing promising compounds;
6	"(iii) conducting clinical trials;
7	"(iv) seeking Food and Drug Adminis-
8	tration approval for drugs to treat addic-
9	tion;
10	"(v) marketing the drug for the treat-
11	ment of addiction;
12	"(vi) urging physicians to use the drug
13	in the treatment of addiction; and
14	"(vii) encouraging insurance compa-
15	nies to reimburse the cost of the drug for the
16	treatment of addiction.
17	"§ 1014. Annual audit and investigation requirements
18	"(a) Periodic Government Accountability Of-
19	FICE AUDITS OF PROGRAMS AND OPERATIONS.—Not later
20	than December 31, 2019, and every 3 years thereafter, the
21	Comptroller General shall—
22	"(1) conduct and supervise an audit and inves-
23	tigation relating to the programs and operations of—
24	"(A) the Office; or

1	"(B) certain programs within the Office, in-
2	cluding—
3	"(i) the High Intensity Drug Traf-
4	ficking Areas Program; and
5	"(iii) the media campaign under sec-
6	$tion\ 1009(d);\ and$
7	"(2) submit to the Director and the appropriate
8	congressional committees a report containing an eval-
9	uation of and recommendations on the—
10	"(A) policies and activities of the programs
11	and operations subject to the audit and inves-
12	tigation;
13	"(B) economy, efficiency, and effectiveness
14	in the administration of the reviewed programs
15	and operations; and
16	"(C) policy or management changes needed
17	to prevent and detect fraud and abuse in such
18	programs and operations.
19	"§ 1015. Authorization of appropriations
20	"There are authorized to be appropriated to carry out
21	this chapter, except as otherwise specified, to remain avail-
22	able until expended, \$18,400,000 for each of fiscal years
23	2019 through 2023.

1	"SUBCHAPTER II—HIGH INTENSITY DRUG
2	TRAFFICKING AREAS PROGRAM
3	"§ 1021. High intensity drug trafficking areas pro-
4	gram
5	"(a) Establishment.—
6	"(1) In general.—There is established in the
7	Office a program to be known as the High Intensity
8	Drug Trafficking Areas Program (in this section re-
9	ferred to as the 'Program').
10	"(2) Purpose.—The purpose of the Program is
11	to reduce drug trafficking and drug production in the
12	United States by—
13	"(A) facilitating cooperation among Fed-
14	eral, State, local, and Tribal law enforcement
15	agencies to share information and implement co-
16	ordinated enforcement activities;
17	"(B) enhancing law enforcement intelligence
18	sharing among Federal, State, local, and Tribal
19	law enforcement agencies;
20	"(C) providing reliable law enforcement in-
21	telligence to law enforcement agencies needed to
22	design effective enforcement strategies and oper-
23	ations; and
24	"(D) supporting coordinated law enforce-
25	ment strategies which maximize use of available

1	resources to reduce the supply of illegal drugs in
2	designated areas and in the United States as a
3	whole.
4	"(b) Designation.—
5	"(1) In general.—The Director, in consultation
6	with the Attorney General, the Secretary of the Treas-
7	ury, the Secretary of Homeland Security, heads of the
8	National Drug Control Program Agencies, and the
9	Governor of each applicable State, may designate any
10	specified area of the United States as a high intensity
11	drug trafficking area.
12	"(2) ACTIVITIES.—After making a designation
13	under paragraph (1) and in order to provide Federal
14	assistance to the area so designated, the Director
15	may—
16	"(A) obligate such sums as are appropriated
17	for the Program;
18	"(B) direct the temporary reassignment of
19	Federal personnel to such area, subject to the ap-
20	proval of the head of the agency that employs
21	such personnel;
22	"(C) take any other action authorized under
23	this chapter to provide increased Federal assist-
24	ance to those areas; and

1	"(D) coordinate activities under this section
2	(specifically administrative, recordkeeping, and
3	funds management activities) with State, local,
4	and Tribal officials.
5	"(c) Petitions for Designation.—The Director
6	shall establish and maintain regulations under which a coa-
7	lition of interested law enforcement agencies from an area
8	may petition for designation as a high intensity drug traf-
9	ficking area (in this section referred to as the 'HIDTA').
10	Such regulations shall provide for a regular review by the
11	Director of the petition, including a recommendation re-
12	garding the merit of the petition to the Director by a panel
13	of qualified, independent experts.
14	"(d) Factors for Consideration.—In considering
15	whether to designate an area under this section as a high
16	intensity drug trafficking area, the Director shall consider,
17	in addition to such other criteria as the Director considers
18	to be appropriate, the extent to which—
19	"(1) the area is a significant center of illegal
20	drug production, manufacturing, importation, or dis-
21	tribution;
22	"(2) State, local, and Tribal law enforcement
23	agencies have committed resources to respond to the
24	drug trafficking problem in the area, thereby indi-

1	cating a determination to respond aggressively to the
2	problem;
3	"(3) drug-related activities in the area are hav-
4	ing a significant harmful impact in the area, and in
5	other areas of the country; and
6	"(4) a significant increase in allocation of Fed-
7	eral resources is necessary to respond adequately to
8	drug-related activities in the area.
9	"(e) Organization of High Intensity Drug Traf-
10	FICKING AREAS.—
11	"(1) Executive board and officers.—To be
12	eligible for funds appropriated under this section,
13	each high intensity drug trafficking area shall be gov-
14	erned by an Executive Board. The Executive Board
15	shall designate a chairman, vice chairman, and any
16	other officers to the Executive Board that it deter-
17	mines are necessary.
18	"(2) Responsibilities.—The Executive Board
19	of a high intensity drug trafficking area shall be re-
20	sponsible for—
21	"(A) providing direction and oversight in
22	establishing and achieving the goals of the high
23	intensity drug trafficking area;
24	"(B) managing the funds of the high inten-
25	sity drug trafficking area;

1	"(C) reviewing and approving all funding
2	proposals consistent with the overall objective of
3	the high intensity drug trafficking area; and
4	"(D) reviewing and approving all reports to

- "(D) reviewing and approving all reports to the Director on the activities of the high intensity drug trafficking area.
- "(3) BOARD REPRESENTATION.—None of the funds appropriated under this section may be expended for any high intensity drug trafficking area, or for a partnership or region of a high intensity drug trafficking area, if the Executive Board for such area, region, or partnership, does not apportion an equal number of votes between representatives of participating agencies and representatives of participating State, local, and Tribal agencies. Where it is impractical for an equal number of representatives of agencies and State, local, and Tribal agencies to attend a meeting of an Executive Board in person, the Executive Board may use a system of proxy votes or weighted votes to achieve the voting balance required by this paragraph.
- "(4) No agency relationship.—The eligibility requirements of this section are intended to ensure the responsible use of Federal funds. Nothing in this section is intended to create an agency relationship be-

1	tween individual high intensity drug trafficking areas
2	and the Federal Government.
3	"(f) Use of Funds.—The Director shall ensure that
4	not more than 5 percent of Federal funds appropriated for
5	the Program are expended for drug treatment programs and
6	not more than 5 percent of the Federal funds appropriated
7	for the Program are expended for drug prevention pro-
8	grams.
9	"(g) Counterterrorism Activities.—
10	"(1) Assistance authorized.—The Director
11	may authorize use of resources available for the Pro-
12	gram to assist Federal, State, local, and Tribal law
13	enforcement agencies in investigations and activities
14	related to terrorism and prevention of terrorism, espe-
15	cially but not exclusively with respect to such inves-
16	tigations and activities that are also related to drug
17	trafficking.
18	"(2) Limitation.—The Director shall ensure—
19	"(A) that assistance provided under para-
20	graph (1) remains incidental to the purpose of
21	the Program to reduce drug availability and
22	carry out drug-related law enforcement activi-
23	ties; and
24	"(B) that significant resources of the Pro-
25	gram are not redirected to activities exclusively

1	related to terrorism, except on a temporary basis
2	under extraordinary circumstances, as deter-
3	mined by the Director.
4	"(h) Role of Drug Enforcement Administra-
5	TION.—The Director, in consultation with the Attorney
6	General, shall ensure that a representative of the Drug En-
7	forcement Administration is included in the Intelligence
8	Support Center for each high intensity drug trafficking
9	area.
10	"(i) Emerging Threat Response Fund.—
11	"(1) In general.—Subject to the availability of
12	appropriations, the Director may expend up to 10
13	percent of the amounts appropriated under this sec-
14	tion on a discretionary basis, in accordance with the
15	criteria established under paragraph (2)—
16	"(A) to respond to any emerging drug traf-
17	ficking threat in an existing high intensity drug
18	$trafficking\ area;$
19	"(B) to establish a new high intensity drug
20	trafficking area; or
21	"(C) to expand an existing high intensity
22	drug trafficking area.
23	"(2) Consideration of impact.—In allocating
24	funds under this subsection, the Director shall con-
25	sider—

1	"(A) the impact of activities funded on re-
2	ducing overall drug traffic in the United States,
3	or minimizing the probability that an emerging
4	drug trafficking threat will spread to other areas
5	of the United States; and
6	"(B) such other criteria as the Director con-
7	siders appropriate.
8	"(j) Annual Hidta Program Budget Submis-
9	SIONS.—As part of the documentation that supports the
10	President's annual budget request for the Office, the Direc-
11	tor shall submit to Congress a budget justification that in-
12	cludes—
13	"(1) the amount proposed for each HIDTA, con-
14	ditional upon a review by the Office of the request
15	submitted by such HIDTA and the performance of
16	such HIDTA, with supporting narrative descriptions
17	and rationale for each request;
18	"(2) a detailed justification that explains—
19	"(A) the reasons for the proposed funding
20	level and how such funding level was determined
21	based on a current assessment of the drug traf-
22	ficking threat in each high intensity drug traf-
23	ficking area;

1	"(B) how such funding will ensure that the
2	goals and objectives of each such area will be
3	achieved; and
4	"(C) how such funding supports the Na-
5	tional Drug Control Strategy; and
6	"(3) the amount of HIDTA funds used to inves-
7	tigate and prosecute organizations and individuals
8	trafficking in each major illicit drug, as identified by
9	the Director, in the prior calendar year, and a de-
10	scription of how those funds were used.
11	"(k) Hidta Annual Evaluation Report.—As part
12	of each National Drug Control Evaluation assessment
13	under section 1006, the Director shall include, for each des-
14	ignated high intensity drug trafficking area, a report
15	that—
16	"(1) describes—
17	"(A) the specific purposes for the high in-
18	tensity drug trafficking area; and
19	"(B) the specific long-term and short-term
20	goals and objectives for the high intensity drug
21	$trafficking\ area;$
22	"(2) includes an evaluation of the performance of
23	the high intensity drug trafficking area in accom-
24	plishing the specific long-term and short-term goals
25	and objectives identified under subparagraph (1)(B);

1	"(3) assesses the number and operation of all fed-
2	erally funded drug enforcement task forces within
3	such high intensity drug trafficking area;
4	"(4) describes—
5	"(A) each Federal, State, local, and Tribal
6	drug enforcement task force operating in such
7	high intensity drug trafficking area;
8	"(B) how such task forces coordinate with
9	each other, with any high intensity drug traf-
10	ficking area task force, and with investigations
11	receiving funds from the Organized Crime and
12	Drug Enforcement Task Force;
13	"(C) what steps, if any, each such task force
14	takes to share information regarding drug traf-
15	ficking and drug production with other federally
16	funded drug enforcement task forces in the high
17	intensity drug trafficking area;
18	"(D) the role of the high intensity drug traf-
19	ficking area in coordinating the sharing of such
20	information among task forces;
21	"(E) the nature and extent of cooperation
22	by each Federal, State, local, and Tribal partici-
23	pant in ensuring that such information is shared
24	among law enforcement agencies and with the
25	high intensity drug trafficking area;

1	"(F) the nature and extent to which infor-
2	mation sharing and enforcement activities are
3	coordinated with joint terrorism task forces in
4	the high intensity drug trafficking area; and
5	"(G) any recommendations for measures
6	needed to ensure that task force resources are uti-
7	lized efficiently and effectively to reduce the
8	availability of illegal drugs in the high intensity
9	drug trafficking areas; and
10	"(5) in consultation with the Director of Na-
11	tional Intelligence—
12	"(A) evaluates existing and planned law en-
13	forcement intelligence systems supported by such
14	high intensity drug trafficking area, or utilized
15	by task forces receiving any funding under the
16	Program, including the extent to which such sys-
17	tems ensure access and availability of law en-
18	forcement intelligence to Federal, State, local,
19	and Tribal law enforcement agencies within the
20	high intensity drug trafficking area and outside
21	of such area;
22	"(B) evaluates the extent to which Federal,
23	State, local, and Tribal law enforcement agencies
24	participating in each high intensity drug traf-
25	ficking area are sharing law enforcement intel-

1	ligence information to assess current drug traf-
2	ficking threats and design appropriate enforce-
3	ment strategies; and
4	"(C) identifies the measures needed to im-
5	prove effective sharing of information and law
6	enforcement intelligence regarding drug traf-
7	ficking and drug production among Federal,
8	State, local, and Tribal law enforcement partici-
9	pating in a high intensity drug trafficking area,
10	and between such agencies and similar agencies
11	outside the high intensity drug trafficking area.
12	"(l) Coordination of Law Enforcement Intel-
13	LIGENCE SHARING WITH ORGANIZED CRIME DRUG EN-
14	FORCEMENT TASK FORCE PROGRAM.—
15	"(1) Drug enforcement intelligence shar-
16	ING.—The Director, in consultation with the Attorney
17	General, shall ensure that any drug enforcement intel-
18	ligence obtained by the Intelligence Support Center
19	for each high intensity drug trafficking area is
20	shared, on a timely basis, with the drug intelligence
21	fusion center operated by the Organized Crime Drug
22	Enforcement Task Force of the Department of Justice.
23	"(2) Certification.—Before the Director
24	awards any funds to a high intensity drug trafficking
25	area, the Director shall certify that the law enforce-

1	ment entities participating in that HIDTA are pro-
2	viding laboratory seizure data to the national clan-
3	destine laboratory database at the El Paso Intel-
4	ligence Center.
5	"(m) Authorization of Appropriations.—There is
6	authorized to be appropriated to the Office to carry out this
7	section \$280,000,000 for each fiscal years 2019 through
8	2023.
9	"(n) Specific Purposes.—
10	"(1) In general.—The Director shall ensure
11	that, of the amounts appropriated for a fiscal year for
12	the Program, at least 2.5 percent is used in high in-
13	tensity drug trafficking areas with severe neighbor-
14	hood safety and illegal drug distribution problems.
15	"(2) REQUIRED USES.—The funds used under
16	paragraph (1) shall be used to ensure the safety of
17	neighborhoods and the protection of communities, in-
18	cluding the prevention of the intimidation of wit-
19	nesses of illegal drug distribution and related activi-
20	ties and the establishment of or support for programs
21	that provide protection or assistance to witnesses in
22	court proceedings.
23	"(3) Best practice models.—The Director

shall work with the HIDTAs to develop and maintain

best practice models to assist State, local, and Tribal

24

1	governments in addressing witness safety, relocation,
2	financial and housing assistance, or any other serv-
3	ices related to witness protection or assistance in
4	cases of illegal drug distribution and related activi-
5	ties. The Director shall ensure dissemination of the
6	best practice models to each HIDTA.
7	"SUBCHAPTER III—DRUG-FREE COMMUNITIES
8	$SUPPORT\ PROGRAM$
9	"§ 1031. Establishment of drug-free communities sup-
10	port program
11	$``(a)\ Establishment.$ —The Director shall establish a
12	program to support communities in the development and
13	implementation of comprehensive, long-term plans and pro-
14	grams to prevent and treat substance use and misuse among
15	youth.
16	"(b) Program.—In carrying out the Program, the Di-
17	rector shall—
18	"(1) make and track grants to grant recipients;
19	"(2) provide for technical assistance and train-
20	ing, data collection, and dissemination of information
21	on state-of-the-art practices that the Director deter-
22	mines to be effective in reducing substance use; and
23	"(3) provide for the general administration of
24	the Program.

1	"(c) Administration.—The Director shall appoint an
2	Administrator to carry out the Program.
3	"(d) Contracting.—The Director may employ any
4	necessary staff and may enter into contracts or agreements
5	with national drug control agencies, including interagency
6	agreements, to delegate authority for the execution of grants
7	and for such other activities necessary to carry out this
8	chapter.
9	"§ 1032. Program authorization
10	"(a) Grant Eligibility.—To be eligible to receive an
11	initial grant or a renewal grant under this subchapter, a
12	coalition shall meet each of the following criteria:
13	"(1) Application.—The coalition shall submit
14	an application to the Administrator in accordance
15	with section $1033(a)(2)$.
16	"(2) Major sector involvement.—
17	"(A) In general.—The coalition shall con-
18	sist of 1 or more representatives of each of the
19	following categories:
20	"(i) Youth.
21	"(ii) Parents.
22	$\it ``(iii) Businesses.$
23	"(iv) The media.
24	" (v) Schools.
25	"(vi) Organizations serving youth.

1	"(vii) Law enforcement.
2	"(viii) Religious or fraternal organiza-
3	tions.
4	"(ix) Civic and volunteer groups.
5	"(x) Health care professionals.
6	"(xi) State, local, or tribal govern-
7	mental agencies with expertise in the field
8	of substance use prevention or substance use
9	disorders (including, if applicable, the State
10	authority with primary authority for sub-
11	stance use and misuse).
12	"(xii) Other organizations involved in
13	reducing the prevalence of substance use and
14	misuse or substance use disorders.
15	"(B) Elected officials.—If feasible, in
16	addition to representatives from the categories
17	listed in subparagraph (A), the coalition shall
18	have an elected official (or a representative of an
19	elected official) from—
20	"(i) the Federal Government; and
21	"(ii) the government of the appropriate
22	State and political subdivision thereof or
23	the governing body or an Indian tribe (as
24	that term is defined in section 4(e) of the

1	Indian Self-Determination Act (25 U.S.C.
2	450b(e))).
3	"(C) Representation.—An individual
4	who is a member of the coalition may serve on
5	the coalition as a representative of not more than
6	1 category listed under subparagraph (A).
7	"(3) Commitment.—The coalition shall dem-
8	onstrate, to the satisfaction of the Administrator—
9	"(A) that the representatives of the coalition
10	have worked together on substance use and mis-
11	use reduction initiatives, which, at a minimum,
12	includes initiatives that target drugs described in
13	section 1037(6)(A), for a period of not less than
14	6 months, acting through entities such as task
15	forces, subcommittees, or community boards; and
16	"(B) substantial participation from volun-
17	teer leaders in the community involved (espe-
18	cially in cooperation with individuals involved
19	with youth such as parents, teachers, coaches,
20	youth workers, and members of the clergy).
21	"(4) Mission and Strategies.—The coalition
22	shall, with respect to the community involved—
23	"(A) have as its principal mission the re-
24	duction of illegal drug use, which, at a min-
25	imum, includes the use of illegal drugs described

1	in section 1037(6)(A), in a comprehensive and
2	long-term manner, with a primary focus on
3	youth in the community;
4	"(B) describe and document the nature and
5	extent of the substance use and misuse problem,
6	which, at a minimum, includes the use and mis-
7	use of drugs described in section 1037(6)(A), in
8	$the\ community;$
9	"(C)(i) provide a description of substance
10	use and misuse prevention and treatment pro-
11	grams and activities, which, at a minimum, in-
12	cludes programs and activities relating to the use
13	and misuse of drugs described in section
14	1037(6)(A), in existence at the time of the grant
15	application; and
16	"(ii) identify substance use and misuse pro-
17	grams and service gaps, which, at a minimum,
18	includes programs and gaps relating to the use
19	and misuse of drugs described in section
20	1037(6)(A), in the community;
21	"(D) develop a strategic plan to reduce sub-
22	stance use and misuse among youth, which, at a
23	minimum, includes the use and misuse of drugs
24	described in section 1037(6)(A), in a comprehen-
25	sive and long-term fashion; and

1	"(E) work to develop a consensus regarding
2	the priorities of the community to combat sub-
3	stance use and misuse among youth, which, at a
4	minimum, includes the use and misuse of drugs
5	described in section $1037(6)(A)$.
6	"(5) Sustainability.—The coalition shall dem-
7	onstrate that the coalition is an ongoing concern by
8	demonstrating that the coalition—
9	"(A) is—
10	$``(i)(I)\ a\ nonprofit\ organization;\ or$
11	"(II) an entity that the Administrator
12	determines to be appropriate; or
13	"(ii) part of, or is associated with, an
14	established legal entity;
15	"(B) receives financial support (including,
16	in the discretion of the Administrator, in-kind
17	contributions) from non-Federal sources; and
18	"(C) has a strategy to solicit substantial fi-
19	nancial support from non-Federal sources to en-
20	sure that the coalition and the programs oper-
21	ated by the coalition are self-sustaining.
22	"(6) Accountability.—The coalition shall—
23	"(A) establish a system to measure and re-
24	port outcomes—

1	"(i) consistent with common indicators
2	and evaluation protocols established by the
3	Administrator; and
4	"(ii) approved by the Administrator;
5	"(B) conduct—
6	"(i) for an initial grant under this
7	subchapter, an initial benchmark survey of
8	drug use among youth (or use local surveys
9	or performance measures available or acces-
10	sible in the community at the time of the
11	grant application); and
12	"(ii) biennial surveys (or incorporate
13	local surveys in existence at the time of the
14	evaluation) to measure the progress and ef-
15	fectiveness of the coalition; and
16	"(C) provide assurances that the entity con-
17	ducting an evaluation under this paragraph, or
18	from which the coalition receives information,
19	has experience—
20	"(i) in gathering data related to sub-
21	stance use and misuse among youth; or
22	"(ii) in evaluating the effectiveness of
23	community anti-drug coalitions.

1	"(7) Additional Criteria.—The Director shall
2	not impose any eligibility criteria on new applicants
3	or renewal grantees not provided in this chapter.
4	"(b) Grant Amounts.—
5	"(1) In general.—
6	"(A) Grants.—
7	"(i) In general.—Subject to clause
8	(iv), for a fiscal year, the Administrator
9	may grant to an eligible coalition under
10	this paragraph, an amount not to exceed the
11	amount of non-Federal funds raised by the
12	coalition, including in-kind contributions,
13	for that fiscal year.
14	"(ii) Suspension of grants.—If such
15	grant recipient fails to continue to meet the
16	criteria specified in subsection (a), the Ad-
17	ministrator may suspend the grant, after
18	providing written notice to the grant recipi-
19	ent and an opportunity to appeal.
20	"(iii) Renewal grants.—Subject to
21	clause (iv), the Administrator may award a
22	renewal grant to a grant recipient under
23	this subparagraph for each fiscal year fol-
24	lowing the fiscal year for which an initial
25	grant is awarded, in an amount not to ex-

1	ceed the amount of non-Federal funds raised
2	by the coalition, including in-kind contribu-
3	tions, for that fiscal year, during the 4-year
4	period following the period of the initial
5	grant.
6	"(iv) Limitation.—The amount of a
7	grant award under this subparagraph may
8	not exceed \$125,000 for a fiscal year.
9	"(B) Coalition Awards.—
10	"(i) In general.—Except as provided
11	in clause (ii), the Administrator may, with
12	respect to a community, make a grant to 1
13	eligible coalition that represents that com-
14	munity.
15	"(ii) Exception.—The Administrator
16	may make a grant to more than 1 eligible
17	coalition that represents a community if—
18	"(I) the eligible coalitions dem-
19	onstrate that the coalitions are collabo-
20	rating with one another; and
21	"(II) each of the coalitions has
22	independently met the requirements set
23	forth in subsection (a).
24	"(2) Rural coalition grants.—
25	"(A) In general.—

1	"(i) In General.—In addition to
2	awarding grants under paragraph (1), to
3	stimulate the development of coalitions in
4	sparsely populated and rural areas, the Ad-
5	ministrator may award a grant in accord-
6	ance with this section to a coalition that
7	represents a county with a population that
8	does not exceed 30,000 individuals. In
9	awarding a grant under this paragraph, the
10	Administrator may waive any requirement
11	under subsection (a) if the Administrator
12	considers that waiver to be appropriate.
13	"(ii) Matching requirement.—Sub-
14	ject to subparagraph (C), for a fiscal year,
15	the Administrator may grant to an eligible
16	coalition under this paragraph, an amount
17	not to exceed the amount of non-Federal
18	funds raised by the coalition, including in-
19	kind contributions, for that fiscal year.
20	"(iii) Suspension of grants.—If
21	such grant recipient fails to continue to
22	meet any criteria specified in subsection (a)
23	that has not been waived by the Adminis-
24	trator pursuant to clause (i), the Adminis-

trator may suspend the grant, after pro-

1	viding written notice to the grant recipient
2	and an opportunity to appeal.
3	"(B) Renewal Grants.—The Adminis-
4	trator may award a renewal grant to an eligible
5	coalition that is a grant recipient under this
6	paragraph for each fiscal year following the fis-
7	cal year for which an initial grant is awarded,
8	in an amount not to exceed the amount of non-
9	Federal funds raised by the coalition, including
10	in-kind contributions, during the 4-year period
11	following the period of the initial grant.
12	"(C) Limitations.—
13	"(i) Amount.—The amount of a grant
14	award under this paragraph shall not ex-
15	ceed \$125,000 for a fiscal year.
16	"(ii) AWARDS.—With respect to a
17	county referred to in subparagraph (A), the
18	Administrator may award a grant under
19	this section to not more than 1 eligible coa-
20	lition that represents the county.
21	"(3) Additional grants.—
22	"(A) In general.—Subject to subpara-
23	graph (F), the Administrator may award an ad-
24	ditional grant under this paragraph to an eligi-
25	ble coalition awarded a grant under paragraph

- (1) or (2) for any first fiscal year after the end of the 4-year period following the period of the initial grant under paragraph (1) or (2), as the case may be.
 - "(B) Scope of Grants.—A coalition awarded a grant under paragraph (1) or (2), including a renewal grant under such paragraph, may not be awarded another grant under such paragraph, and is eligible for an additional grant under this section only under this paragraph.
 - "(C) NO PRIORITY FOR APPLICATIONS.—The Administrator may not afford a higher priority in the award of an additional grant under this paragraph than the Administrator would afford the applicant for the grant if the applicant were submitting an application for an initial grant under paragraph (1) or (2) rather than an application for a grant under this paragraph.
 - "(D) RENEWAL GRANTS.—Subject to subparagraph (F), the Administrator may award a renewal grant to a grant recipient under this paragraph for each of the fiscal years of the 4fiscal-year period following the fiscal year for which the initial additional grant under sub-

1	paragraph (A) is awarded in an amount not to
2	exceed amounts as follows:
3	"(i) For the first and second fiscal
4	years of that 4-fiscal-year period, the
5	amount equal to 80 percent of the non-Fed-
6	eral funds, including in-kind contributions,
7	raised by the coalition for the applicable fis-
8	cal year.
9	"(ii) For the third and fourth fiscal
10	years of that 4-fiscal-year period, the
11	amount equal to 67 percent of the non-Fed-
12	eral funds, including in-kind contributions,
13	raised by the coalition for the applicable fis-
14	cal year.
15	"(E) Suspension.—If a grant recipient
16	under this paragraph fails to continue to meet
17	the criteria specified in subsection (a), the Ad-
18	ministrator may suspend the grant, after pro-
19	viding written notice to the grant recipient and
20	an opportunity to appeal.
21	"(F) Limitation.—The amount of a grant
22	award under this paragraph may not exceed
23	\$125,000 for a fiscal year.
24	"(4) Process for suspension.—A grantee
25	shall not be suspended or terminated under para-

1	$graph\ (1)(A)(ii),\ (2)(A)(iii),\ or\ (3)(C)\ unless\ that$
2	grantee is afforded a fair, timely, and independent
3	appeal prior to such suspension or termination.
4	"(c) Treatment of Funds for Coalitions Rep-
5	RESENTING CERTAIN ORGANIZATIONS.—Funds appro-
6	priated for the substance use and misuse activities of a coa-
7	lition that includes a representative of the Bureau of Indian
8	Affairs, the Indian Health Service, or a tribal government
9	agency with expertise in the field of substance use preven-
10	tion may be counted as non-Federal funds raised by the
11	coalition for purposes of this section.
12	"(d) Priority in Awarding Grants.—In awarding
13	grants under subsection (b)(1)(A)(i), priority shall be given
14	to a coalition serving economically disadvantaged areas.
15	"§ 1033. Information collection and dissemination
16	with respect to grant recipients
17	"(a) Coalition Information.—
18	"(1) General auditing authority.—For the
19	purpose of audit and examination, the Adminis-
20	trator—
21	"(A) shall have access to any books, docu-
22	ments, papers, and records that are pertinent to
23	any grant or grant removal request under this
	any grant or grant renewal request under this

1	"(B) may periodically request information
2	from a grant recipient to ensure that the grant
3	recipient meets the applicable criteria under sec-
4	$tion \ 1032(a).$
5	"(2) APPLICATION PROCESS.—The Administrator
6	shall issue a request for proposal regarding, with re-
7	spect to the grants awarded under section 1032, the
8	application process, grant renewal, and suspension or
9	withholding of renewal grants. Each application
10	under this paragraph shall be in writing and shall be
11	subject to review by the Administrator.
12	"(3) Reporting.—The Administrator shall, to
13	the maximum extent practicable and in a manner
14	consistent with applicable law, minimize reporting
15	requirements by a grant recipient and expedite any
16	application for a renewal grant made under this sub-
17	chapter.
18	"(b) Data Collection and Dissemination.—
19	"(1) In general.—The Administrator may col-
20	lect data from—
21	"(A) national substance use and misuse or-
22	ganizations that work with eligible coalitions,
23	community anti-drug coalitions, departments or
24	agencies of the Federal Government, or State or

1	local governments and the governing bodies of
2	Indian tribes; and
3	"(B) any other entity or organization that
4	carries out activities that relate to the purposes
5	of the Program.
6	"(2) Activities of administrator.—The Ad-
7	ministrator may—
8	"(A) evaluate the utility of specific initia-
9	tives relating to the purposes of the Program;
10	"(B) conduct an evaluation of the Program;
11	and
12	"(C) disseminate information described in
13	this subsection to—
14	"(i) eligible coalitions and other sub-
15	stance use prevention organizations; and
16	"(ii) the general public.
17	"(3) Consultation.—The Administrator shall
18	carry out activities under this subsection in consulta-
19	tion with the National Community Antidrug Coali-
20	$tion\ Institute.$
21	"(4) Limitation on use of certain funds
22	FOR EVALUATION OF PROGRAM.—Amounts for activi-
23	ties under paragraph (2)(B) may not be derived from
24	amounts under section 1038(a) except for amounts

1	that are available under section 1038(b) for adminis-
2	trative costs.
3	"§ 1034. Technical assistance and training
4	"(a) In General.—
5	"(1) TECHNICAL ASSISTANCE AND AGREE-
6	MENTS.—With respect to any grant recipient or other
7	organization, the Administrator may—
8	"(A) offer technical assistance and training;
9	and
10	"(B) enter into contracts and cooperative
11	agreements.
12	"(2) Coordination of Programs.—The Ad-
13	ministrator may facilitate the coordination of pro-
14	grams between a grant recipient and other organiza-
15	tions and entities.
16	"(b) Training.—The Administrator may provide
17	training to any representative designated by a grant recipi-
18	ent in—
19	"(1) coalition building;
20	"(2) task force development;
21	"(3) mediation and facilitation, direct service,
22	assessment and evaluation; or
23	"(4) any other activity related to the purposes of
24	the Program.

1	3 1035. Supplemental grants for coalition mentoring
2	activities
3	"(a) Authority to Make Grants.—As part of the
4	program established under section 1031, the Director may
5	award an initial grant under this subsection, and renewal
6	grants under subsection (f), to any coalition awarded a
7	grant under section 1032 that meets the criteria specified
8	in subsection (d) in order to fund coalition mentoring ac-
9	tivities by such coalition in support of the program.
10	"(b) Treatment With Other Grants.—
11	"(1) Supplement.—A grant awarded to a coali-
12	tion under this section is in addition to any grant
13	awarded to the coalition under section 1032.
14	"(2) Requirement for basic grant.—A coali-
15	tion may not be awarded a grant under this section
16	for a fiscal year unless the coalition was awarded a
17	grant or renewal grant under section 1032(b) for that
18	fiscal year.
19	"(c) APPLICATION.—A coalition seeking a grant under
20	this section shall submit to the Administrator an applica-
21	tion for the grant in such form and manner as the Adminis-
22	trator may require.
23	"(d) Criteria.—A coalition meets the criteria speci-
24	fied in this subsection if the coalition—
25	"(1) has been in existence for at least 5 years;

1	"(2) has achieved, by or through its own efforts,
2	measurable results in the prevention and treatment of
3	substance use and misuse among youth;
4	"(3) has staff or members willing to serve as
5	mentors for persons seeking to start or expand the ac-
6	tivities of other coalitions in the prevention and treat-
7	ment of substance use and misuse;
8	"(4) has demonstrable support from some mem-
9	bers of the community in which the coalition men-
10	toring activities to be supported by the grant under
11	this section are to be carried out; and
12	"(5) submits to the Administrator a detailed
13	plan for the coalition mentoring activities to be sup-
14	ported by the grant under this section.
15	"(e) Use of Grant Funds.—A coalition awarded a
16	grant under this section shall use the grant amount for
17	mentoring activities to support and encourage the develop-
18	ment of new, self-supporting community coalitions that are
19	focused on the prevention and treatment of substance use
20	and misuse in such new coalitions' communities. The men-
21	toring coalition shall encourage such development in ac-
22	cordance with the plan submitted by the mentoring coali-
23	$tion\ under\ subsection\ (d) (5).$
24	"(f) Renewal Grants.—The Administrator may
25	make a renewal grant to any coalition awarded a grant

- 1 under subsection (a), or a previous renewal grant under
- 2 this subsection, if the coalition, at the time of application
- 3 for such renewal grant—
- 4 "(1) continues to meet the criteria specified in 5 subsection (d); and
- "(2) has made demonstrable progress in the development of one or more new, self-supporting community coalitions that are focused on the prevention
 and treatment of substance use and misuse.

10 "(q) Grant Amounts.—

- "(1) In GENERAL.—Subject to paragraphs (2) and (3), the total amount of grants awarded to a coalition under this section for a fiscal year may not exceed the amount of non-Federal funds raised by the coalition, including in-kind contributions, for that fiscal year. Funds appropriated for the substance use and misuse activities of a coalition that includes a representative of the Bureau of Indian Affairs, the Indian Health Service, or a tribal government agency with expertise in the field of substance use prevention may be counted as non-Federal funds raised by the coalition.
- "(2) Initial grants.—The amount of the initial grant awarded to a coalition under subsection (a) may not exceed \$75,000.

1	"(3) Renewal grants.—The total amount o
2	renewal grants awarded to a coalition under sub-
3	section (f) for any fiscal year may not exceed \$75,000
4	"(h) Fiscal Year Limitation on Amount Avail-
5	ABLE FOR GRANTS.—The total amount available for grants
6	under this section, including renewal grants under sub-
7	section (f), in any fiscal year may not exceed the amount
8	equal to five percent of the amount authorized to be appro-
9	priated by section 1038 for that fiscal year.
10	"(i) Priority in Awarding Initial Grants.—In
11	awarding initial grants under this section, priority shall
12	be given to a coalition that expressly proposes to provide
13	mentorship to a coalition or aspiring coalition serving eco-
14	nomically disadvantaged areas.
15	"§ 1036. Authorization for National Community Anti
16	drug Coalition Institute
17	"(a) In General.—The Director shall, using amounts
18	authorized to be appropriated by subsection (d), make a
19	competitive grant to provide for the continuation of the Na
20	$tional\ Community\ Anti-drug\ Coalition\ Institute.$
21	"(b) Eligible Organizations.—An organization eli
22	gible for the grant under subsection (a) is any national non-
23	profit organization that represents, provides technical as-

24 sistance and training to, and has special expertise and

1	broad, national-level experience in community antidrug
2	coalitions under this subchapter.
3	"(c) Use of Grant Amount.—The organization that
4	receives the grant under subsection (a) shall continue a Na-
5	$tional\ Community\ Anti-Drug\ Coalition\ Institute\ to-$
6	"(1) provide education, training, and technical
7	assistance for coalition leaders and community teams,
8	with emphasis on the development of coalitions serv-
9	ing economically disadvantaged areas;
10	"(2) develop and disseminate evaluation tools,
11	mechanisms, and measures to better assess and docu-
12	ment coalition performance measures and outcomes;
13	and
14	"(3) bridge the gap between research and prac-
15	tice by translating knowledge from research into prac-
16	$tical\ information.$
17	"(d) Authorization of Appropriations.—The Di-
18	rector shall, using amounts authorized to be appropriated
19	by section 1038, make a grant of \$2,000,000 under sub-
20	section (a), for each of the fiscal years 2019 through 2023.
21	"§ 1037. Definitions
22	"In this subchapter:
23	"(1) Administrator.—The term 'Adminis-
24	trator' means the Administrator appointed by the Di-
25	$rector\ under\ section\ 1031(c).$

1	"(2) Community.—The term 'community' shall
2	have the meaning provided that term by the Adminis-
3	trator.
4	"(3) Eligible coalition.—The term 'eligible
5	coalition' means a coalition that meets the applicable
6	$criteria\ under\ section\ 1032(a).$
7	"(4) Grant recipient.—The term 'grant recipi-
8	ent' means the recipient of a grant award under sec-
9	tion 1032.
10	"(5) Program.—The term 'Program' means the
11	$program\ established\ under\ section\ 1031 (a).$
12	"(6) Substance use and misuse.—The term
13	'substance use and misuse' means—
14	"(A) the illegal use or misuse of drugs, in-
15	cluding substances for which a listing is in effect
16	under any of schedules I through V under section
17	202 of the Controlled Substances Act (21 U.S.C.
18	812);
19	"(B) the misuse of inhalants or over the
20	counter drugs; or
21	"(C) the use of alcohol, tobacco, or other re-
22	lated product as such use is prohibited by State
23	or local law.
24	"(7) Youth.—The term 'youth' shall have the
25	meaning provided that term by the Administrator.

1	"§ 1038. Drug-free communities reauthorization
2	"(a) Authorization of Appropriations.—There
3	are authorized to be appropriated to the Office to carry out
4	this subchapter \$99,000,000 for each of fiscal years 2019
5	through 2023.
6	"(b) Administrative Costs.—Not more than 8 per-
7	cent of the funds appropriated for this subchapter may be
8	used by the Office or, in the discretion of the Director, and
9	agency delegated to carry out the program under section
10	1031(d) to pay for administrative costs associated with car-
11	rying out the program.".
12	(d) Technical and Conforming Amendment.—The
13	table of chapters for subtitle I of title 31, United States
14	Code, is amended by adding at the end the following new
15	item:
	"10. Office of National Drug Control 1001"
16	SEC. 3. REPEALS.
17	The following provisions are repealed:
18	(1) Section 203 of the Office of National Drug
19	Control Policy Reauthorization Act of 2006 (Public
20	Law 109–469; 21 U.S.C. 1708a).
21	(2) Title VIII of the Office of National Drug
22	Control Policy Reauthorization Act of 2006 (Public
23	Law 109_469)

1	(3) Section 1105 of the Office of National Drug
2	Control Policy Reauthorization Act of 2006 (Public
3	Law 109-469; 21 U.S.C. 1701 note).
4	(4) Section 1110 of Office of National Drug Con-
5	trol Policy Reauthorization Act of 2006 (Public Law
6	109–469; 21 U.S.C. 1705 note).
7	(5) Section 1110A of the Office of National Drug
8	Control Policy Reauthorization Act of 2006 (Public
9	Law 109-469; 21 U.S.C. 1705 note).
10	(6) Section 4 of Public Law 107–82 (21 U.S.C.
11	1521 note).
12	SEC. 4. OPIOID CRISIS RESPONSE.
13	(a) Emerging Threat Designation.—The Director
14	shall designate opioids and opioid analogues as emerging
15	threats, in accordance with section 1009 of title 31, United
16	States Code, as added by section 2(b).
17	(b) Opioid Response Plan.—
18	(1) Issuance.—Not later than 60 days after the
19	date of the enactment of this Act, the Director shall
20	publish, make publicly available, and notify the
21	President and the appropriate congressional commit-
22	tees of, the plan required under section 1009 of title
23	31, United States Code, as added by section 2(b), to
24	be designated as the "National Opioid Crisis Re-
25	sponse Plan".

1	(2) Contents.—The Director shall ensure the
2	plan establishes measurable goals, including reducing
3	fatal and non-fatal overdoses, and includes the fol-
4	lowing:
5	(A) Initiatives to ensure the United States
6	mail is effectively screened to prevent illicit
7	drugs from entering the United States, includ-
8	ing—
9	(i) designating the United States Post-
10	al Service as a National Drug Control Pro-
11	gram Agency;
12	(ii) directing the United States Postal
13	Service and any other related National
14	Drug Control Program Agency to take any
15	appropriate actions necessary to reduce the
16	amount of illicit drugs entering the country;
17	and
18	(iii) developing an international co-
19	ordination plan, in accordance with section
20	1010 of such title 31, United States Code, as
21	added by section 2(b)), to include efforts to
22	address international drug control initia-
23	tives and strengthen bilateral and multilat-
24	eral strategies to reduce illicit drugs and
25	precursor chemicals from entering the

1	United States through international mail or
2	across land borders or ports of entry.
3	(B) Support for universal adoption of evi-
4	dence-based prescribing guidelines, including—
5	(i) establishing a task force to supple-
6	ment existing prescribing guidelines with
7	evidence-based standards and to facilitate,
8	coordinate, and, as appropriate, conduct re-
9	search to inform such guidelines;
10	(ii) encouraging the adoption of evi-
11	dence-based prescribing guidelines by each
12	relevant agency, State and local govern-
13	ments, and private sector organizations;
14	(iii) issuing guidance to National
15	Drug Control Program Agencies to, as ap-
16	propriate, revise regulations to ensure pro-
17	fessionals have effective continuing edu-
18	cation requirements; and
19	(iv) disseminating and encouraging the
20	adoption of best practices and evidence-
21	based guidelines for effective prescribing
22	practices.
23	(C) A program to monitor the prescription
24	drug market and illicit drug market for changes

1	in trends relevant to reducing the supply or de-
2	mand of such drugs.
3	(D) An initiative to facilitate and coordi-
4	nate Federal, State and local government initia-
5	tives, studies, and pilot or demonstration pro-
6	grams designed to evaluate the benefits of drug
7	courts and related programs that reduce sub-
8	stance use prevalence.
9	(E) Programs, developed in coordination
10	with the private sector, to—
11	(i) facilitate the development of treat-
12	ment and deterrent products, in accordance
13	with section 1010(c) of title 31, United
14	States Code, as added by section 2(b); and
15	(ii) encourage the expansion of medica-
16	tion disposal programs and technology.
17	(F) Initiatives to encourage the National
18	Drug Control Program Agencies and the pro-
19	gram established under section 1010(d) of title
20	31, United States Code, as added by section
21	2(b)—
22	(i) to prioritize the development of sen-
23	tencing standards or model codes for traf-
24	ficking opioids and opioid analogues; and

1 (ii) to advise States on establishing
2 laws and policies to address opioid issues
3 based on the recommendations developed
4 and set forth by the President's Commission
5 on Combating Drug Addiction and the
6 Opioid Crisis.
7 (G) Working groups, established in accord
8 ance with section 1010 of title 31, United States
9 Code, as added by section 2(b), to develop stand
ards, and encourage the use of such standards
for the collection of data necessary to understand
and monitor the opioid crisis, including—
(i) State medical examiner reports or
deaths caused by overdoses and related sta
15 tistical data; and
16 (ii) first responder opioid intoxication
17 incidents.
(H) A program to identify successful college
recovery programs, including sober housing pro-
grams that provide a shared living residence free
of alcohol or illicit drug use for individuals re
covering from drug or alcohol addiction and sub-
stance use disorders, on college campuses and
24 disseminate best practices to Colleges and Uni

1	versities to increase the number and capacity of
2	such programs.
3	(I) Convening working groups, consisting of
4	the appropriate National Drug Control Program
5	Agencies, State, local and Tribal governments,
6	and other appropriate stakeholders, established
7	in accordance with section 1010 of title 31,
8	United States Code—
9	(i) to support Prescription Drug Moni-
10	toring Programs by—
11	(I) facilitating the sharing of pro-
12	gram data among States and Federal
13	prescription drug monitoring pro-
14	grams to ensure interoperability of
15	such programs;
16	(II) assisting States in increasing
17	utilization of such programs;
18	(III) facilitating efforts to incor-
19	porate available overdose and naloxone
20	deployment data into such programs;
21	(IV) evaluating barriers to inte-
22	grating program data with electronic
23	health records; and
24	(V) offering recommendations to
25	address identified barriers; and

1	(ii) to develop standards, and encour-
2	age the use of such standards, for the collec-
3	tion of data necessary to understand and
4	monitor the opioid crisis, including—
5	(I) State medical examiner re-
6	ports on deaths caused by overdoses
7	and related statistical data; and
8	(II) first responder opioid intoxi-
9	$cation\ incidents.$
10	(J) Research initiatives, to be initiated not
11	later than 30 days after the issuance of the plan,
12	to evaluate the uses and barriers to use of and
13	the effects of improving the following programs:
14	(i) Medication Assisted Treatment.
15	(ii) Data collection systems used to
16	confirm opioid use by individuals who have
17	been arrested or hospitalized.
18	(K) A requirement for an Advisory Com-
19	mittee on Substance Use Disorder Treatment
20	Standards, to be established not later than 120
21	days after the issuance of the plan, to promul-
22	gate model evidence-based standards for sub-
23	stance use disorder treatment and recovery fa-
24	cilities which—
25	(i) shall be chaired by the Director;

1	(ii) shall include as members of the ad-
2	visory committee representatives of the rel-
3	evant National Drug Control Program
4	Agencies;
5	(iii) may include as members of the
6	advisory committee government regulators,
7	State representatives, consumer representa-
8	tives, substance use disorder treatment pro-
9	viders, recovery residence owners and opera-
10	tors, and purchasers of substance use dis-
11	order treatments; and
12	(iv) shall ensure such model standards
13	are promulgated no later than 2 years after
14	the date of the issuance of the plan.
15	(c) Recommendations.—Not later than 1 year after
16	the date of the enactment of this Act, the Director shall sub-
17	mit to Congress a report on the results of the initiatives
18	conducted under subsection $(b)(2)(K)$ and recommendations
19	based on such results.
20	SEC. 5. EXCEPTIONS AND RULES OF CONSTRUCTION.
21	(a) Rules of Construction.—Nothing in this Act,
22	or the amendments made by this act shall be construed as
23	derogating the authorities and responsibilities of the Direc-
24	tor of National Intelligence or the Director of the Central
25	Intelligence Agency contained in the National Security Act

```
1 of 1947 (50 U.S.C. 401 et seg.), the Central Intelligence
 2 Agency Act of 1949 (50 U.S.C. 403a et seg.), or any other
 3 law.
 4
        (b) Inapplicability to Certain Programs.—This
   Act, and the amendments made by this Act, shall not apply
    to the National Intelligence Program and the Military In-
    telligence Program, unless such program or an element of
 8
    such program is designated as a National Drug Control
   Program—
10
             (1) by the President; or
11
             (2) jointly by—
12
                  (A) in the case of the National Intelligence
13
             Program, the Director and the Director of Na-
14
             tional Intelligence; or
15
                  (B) in the case of the Military Intelligence
             Program, the Director, the Director of National
16
17
             Intelligence, and the Secretary of Defense.
18
        (c) Classified Information.—Any contents of any
19
    report required under this Act or the amendments made by
20
    this Act that involve information properly classified under
    criteria established by an Executive order shall be presented
    to Congress separately from the rest of such report.
23
    SEC. 6. GAO STUDY AND REPORTS.
24
         (a) Reports.—
```

1	(1) Initial.—Not later than 3 years after the
2	date of the enactment of this Act, the Comptroller
3	General shall provide an initial report to the appro-
4	priate Congressional Committees.
5	(2) Final.—Not later than 6 years after the date
6	of the enactment of this Act, the Comptroller General
7	shall provide a final report to the appropriate Con-
8	$gressional\ Committees.$
9	(b) Contents of Report.—The reports described in
10	subsection (a) shall include the following:
11	(1) A review of the implementation of the edu-
12	cation and outreach campaign for emerging threats,
13	including—
14	(A) whether the objectives of the campaign
15	and the media campaign have been met during
16	the relevant period; and
17	(B) whether the Office took steps to ensure
18	that the campaign operated in an efficient and
19	effective manner consistent with the overall strat-
20	egy and focus of the campaign.
21	(2) A review of the adherence to policies and
22	practices implemented to ensure that Federal funds
23	were used responsibly to purchase advertising time
24	and space and eliminate the potential for waste,
25	fraud and abuse.

1	(3) An evaluation of the most recent, applicable
2	National Drug Control Strategy, including whether
3	the National Drug Control Strategy met the require-
4	ments of section 1005 of title 31, United States Code,
5	as added by section $2(b)$.
6	(4) An evaluation of whether the required annual
7	assessments prepared by the Office met the require-
8	ments of section 1006 of title 31, United States Code,
9	as added by section $2(b)$.
10	(5) Such other matters as the Comptroller Gen-
11	eral determines to be appropriate.
12	SEC. 7. DEFINITIONS.
13	In this Act, the terms "appropriate congressional com-
14	mittees", "Director", "drug", "illicit drug use", "illicit
15	drugs", and "National Drug Control Program Agencies"
16	have the meaning given those terms in section 1001 of title
17	31, United States Code.

Union Calendar No. 596

115TH CONGRESS H. R. 5925

[Report No. 115-767, Part I]

BILL

To codify provisions relating to the Office of National Drug Control, and for other purposes.

June 20, 2018

Reported from the Committee on Oversight and Government Reform with an amendment

June 20, 2018

The Committees on Energy and Commerce, Foreign Affairs, the Judiciary, Intelligence (Permanent Select), and Appropriations discharged; committed to the Committee of the Whole House on the State of the Unionand ordered to be printed